

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

IVD 925 D

U. S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/051900

INTERNATIONAL APPLICATION NO.
PCT/FR96/01666

INTERNATIONAL FILING DATE
October 24, 1996

PRIORITY DATE CLAIMED
October 24, 1995

TITLE OF INVENTION

**INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THE PHARMACEUTICAL
COMPOSITIONS CONTAINING THEM**

APPLICANT(S) FOR DO/EO/US

Loïc Foulon, Georges Garcia, Claudine Serradeil-Le Gal and Gérard Valette

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371 (c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ A translation of the annexes (see 16 (3) and (4) below for a description of the contents of the annexes) to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
 - (1) Citation of References
 - (2) Information Disclosure Statement by Applicant (Form PTO-1449)
 - (3) English translation of the claims as amended under Article 34 PCT
 - (4) English translation of pages 1, 2, 3, 4, 5, 6 as amended under Article 34 PCT


U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO PCT/FR96/01666		ATTORNEY'S DOCKET NUMBER IVD 925 D	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5)): Search Report has been prepared by the EPO or JPO. \$930.00 International preliminary examination fee paid to USPTO (37CFR 1.482) \$720.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$790.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,070.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4). \$98.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	25-20 =	5	x \$22.00	\$ 110.00	
Independent claims	3- 3 =	0	x \$82.00	\$ -	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 1,040.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 1,040.00	
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$	
TOTAL NATIONAL FEE =				\$ 1,040.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 40.00	
TOTAL FEES ENCLOSED =				\$ 1,080.00	
				Amount to be refunded:	\$
				Charged	\$1,080.00

- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 19-0091 in the amount of \$ 1,080.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0091. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Michael D. Alexander
 Patent Department
 Sanofi Pharmaceuticals, Inc.
 9 Great Valley Parkway
 P.O. Box 3026
 Malvern, PA 19355


 SIGNATURE
 DATE 9/17/98
 Michael D. Alexander
 NAME
 36,080
 REGISTRATION NUMBER
 (610) 889-8802
 TELEPHONE NUMBER

88 Rec'd PCT/PTO 17 APR 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Filing under 35 U.S.C. § 371
 Corresponding to International
 Application Serial No.: PCT/FR96/01666

Applicants: Loïc Foulon, Georges Garcia,
 Claudine Serradeil-Le Gal and
 Gérard Valette

International Filing Date: October 24, 1996

For: INDOLIN-2-ONE DERIVATIVES,
 PROCESS FOR THEIR PRODUCTION AND
 THE PHARMACEUTICAL
 COMPOSITIONS CONTAINING THEM

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label Number: EH609996142US

Date of Deposit: April 17, 1998

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above and is addressed to: Asst. Commissioner for Patents, Box PCT, Attn: DO/US, Washington, DC 20231.


 Signature

Assistant Commissioner for Patents
 Box PCT
 Attn: DO/US
 Washington, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the Specification

Please amend the specification as follows:

On page 38, line 7, "40°" should read as "40°C".

On page 47, line 33, "hydrazine" should read as "hydrazide".

On page 57, line 16, "65°" should read as "65°C".

On page 60, Table 1 (Continuation 2), for Examples 24 and 25 the terms
 "-CONHC(CH₃)₃" and "-(CH₂)₃-" should read as "-CONHC(CH₃)₃" and "-(CH₂)₃-"
 respectively.

On page 62, line 18, "1,4 cyclohexadiene" should read as "1,4- cyclohexadiene".

On page 69, Table 2, for Example 46, the term "H₂O" should read as "H₂O".

In the Claims


88 Rec'd PCT/PTO 17 APR 1998

Please amend claims 8 and 15 and add new claims 19 to 25 as follows before calculating the filing fee for the above-identified application:

8. (Amended) Process for the preparation of a compound of formula (I) according to [any one of] Claim[s] 1 [to 5 and 7], characterized in that:

(1) either when $Z = NR_{11}R_{12}$, in which R_{11} and R_{12} are as defined for (1):


(1a) when at least one of the R_{11} and R_{12} radicals is different from hydrogen, a compound of formula:



in which R_1 , R_2 , R_3 , R_4 , W , Cy and T are as defined for (I) and in which X is a halogen or a sulphonic acid derivative is reacted with a derivative of formula ZH in a solvent selected from dimethylformamide, tetrahydrofuran or acetonitrile, at temperatures of between 0° and $120^\circ C$;


(1b) when R_{11} and $R_{12} = H$, the compound (IIA), in which X is an azido, is reduced to amino;

(2) or, when $Z = -COOH$, a compound of formula:




in which R_1 , R_2 , W , R_3 , R_4 and Cy are as defined for (I) and T' represents $T-CH_2-$, is oxidized in an acid solvent at a temperature of between $0^\circ C$ and $100^\circ C$, alkali metal dichromates or alkali metal or alkaline-earth metal permanganates;

(3) or a compound of formula:




in which R_1 , R_2 , Cy, T and Z are as defined for (I), is reacted with a compound of formula:




in which W, R_3 and R_4 are as defined for (I) and Hal represents a halogen atom, in an anhydrous solvent in the presence of a metal hydride or an alkali metal alkoxide at temperatures of between -40° and 25°C ;

(4) or, when $Z = -\text{COOH}$, a compound of formula:




in which R_1 , R_2 and Cy are as defined above for (I) and T' represents $T-\text{CH}_2$, is oxidized [to (I)], then the acid thus obtained of formula:



in which R_1 , R_2 , Cy and T are as defined above for (I), is subsequently optionally protected by a protective group for the carboxylic acid, in order to obtain the intermediate of formula:

004600-019



15. (Amended) Pharmaceutical composition according to [any one of] Claim[s] 9 [to 14] also containing another active principle.

--19. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.--

--20. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.--

--21. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.--

--22. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 4.--

--23. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 5.--

--24. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 6.--

--25. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 7.--

REMARKS


The specification has been amended in order to correct various obvious typographical errors.

Claims 8 and 15 have been amended in order to limit the multiple dependencies of the claims.

New claims 19-25 have been added. Support for these claims occurs, for example, on page 2, lines 24-25 of the specification wherein it is stated that the compounds of the invention exhibit affinity for the vasopressin and/or oxytocin receptors.

Respectfully submitted,

Date: April 17, 1998


Michael D. Alexander,
Registration No. 36,080

Address:
Patent Department
Sanofi Pharmaceuticals, Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355
Telephone No. (610) 889-8802
Facsimile: (610) 889-8799

09051000-044198


Indolin-2-one derivatives, process for their production and the pharmaceutical compositions containing them

The subject of the present invention is new indolin-2-one derivatives and a process for their preparation. These new derivatives possess an affinity for vasopressin and/or oxytocin receptors and can thus constitute active principles of pharmaceutical compositions.

Vasopressin is a hormone known for its antidiuretic effect and its effect in the regulation of arterial pressure. It stimulates a number of receptor types: V₁ (V_{1a}, V_{1b} or V₃), V₂. These receptors are located in the liver, the vessels (coronary, renal or cerebral), the platelets, the kidney, the uterus, the suprarenal glands, the central nervous system or the hypophysis. Oxytocin has a peptide structure similar to that of vasopressin. The oxytocin receptors are also found on the smooth muscle of the uterus; they are also found on the myoepithelial cells of the mammary gland, in the central nervous system and in the kidney. The localization of the different receptors is described in: Jard S. et al., "Vasopressin and Oxytocin Receptors: an Overview in Progress" in Endocrinology, Imura H. and Shizume K., published by Excerpta Medica, Amsterdam, 1988, 1183-1188 and in the following articles: Presse Médicale, 1987, 16 (10), 481-485, J. Lab. Clin. Med., 1989, 114 (6), 617-632 and Pharmacol. Rev., 1991, 43 (1), 73-108. Vasopressin thus exerts hormonal, cardiovascular, hepatic, renal, antidiuretic and aggregant effects and effects on the central and peripheral nervous systems, on the uterine and intestinal areas and on the ocular and pulmonary system. Oxytocin is involved in parturition, lactation and sexual behaviour.

Antagonists of the V₂ receptors of vasopressin (also known as "AVP-2-antagonists" or "V₂ antagonists") can be recommended as powerful aquaretics which act specifically on renal reabsorption of water without resulting in losses of electrolytes (Na⁺ or K⁺), as induced by the diuretics conventionally used clinically, such as furosemide or hydrochlorothiazide. The latter result, after prolonged treatment, in hypokalaemias and hyponatraemias.

The first antagonist of the V₂ receptors of arginine-vasopressin (hereinafter known as AVP), OPC-31260, is currently in the course of clinical development. Comparison of the effects of OPC-31260 with conventional diuretics, such as furosemide, demonstrates that both in animals (Yoshitaka Y. et al., Br. J. Pharmacol., 1992, 105, 787-791) and in man (Akihiro O. et al., J. Clin. Invest., 1993, 92, 2653-2659, and Akihiro O. et al., J. Pharmacol. Exp. Ther., 1995, 272, 546-551)



in which:

- R₁ and R₂ each independently represent a hydrogen; a hydroxyl; a halogen; a (C₁-C₇)alkyl; a (C₁-C₇)poly-fluoroalkyl; a (C₁-C₇)alkoxy; a (C₁-C₇)alkylthio; a (C₁-C₇)polyfluoroalkoxy; a (C₃-C₇)-cycloalkyloxy; a (C₃-C₇)cycloalkylthio; a cycloalkylmethoxy or a cycloalkyl-methylthio in which the cycloalkyl is C₃-C₇; a phenoxy; a benzyloxy; a nitro; or a cyano;

- R₃ and R₄, independently of one another, substitute the phenyl group one or a number of times and each independently represent a hydrogen; a halogen; a (C₁-C₇) alkyl; a (C₂-C₇)alkenyl; a (C₁-C₇)polyhaloalkyl; a phenyl or a benzyl; a cyano; a nitro; an -NR₅R₆ group; a hydroxy-amino; a hydroxyl; an OR₇ group; an SR₇ group; a -COOR₈ group, a -CONR₉R₁₀ group; or a -CSNR₉R₁₀ group, at least one of the R₃ and R₄ radicals being other than hydrogen;

- R₅ and R₆ each independently represent a hydrogen; a (C₁-C₇)alkyl; a (C₂-C₇)alkenyl; a phenyl; a benzyl; a (C₁-C₇)alkylcarbonyl; a (C₁-C₇)alkylthiocarbonyl; a (C₃-C₇)cycloalkylcarbonyl; a (C₃-C₇)cycloalkylthiocarbonyl; a benzoyl; a thienylcarbonyl; a furylcarbonyl; a (C₁-C₇)alkyloxycarbonyl; a phenoxycarbonyl; a benzyloxy-carbonyl; a carbamoyl or a thiocarbamoyl which is unsubstituted or substituted by R₉ and R₁₀ or alternatively R₅ and R₆ form, with the nitrogen atom to which they are bonded, a heterocyclic group chosen from the pyrrolidine, pyrroline, pyrrole, indoline, indole and piperidine groups;

- R₇ represents a (C₁-C₇)alkyl; a (C₂-C₇)alkenyl; a phenyl; a benzyl; a (C₃-C₇)cycloalkyl; a (C₁-C₇)poly-fluoroalkyl; a formyl; a (C₁-C₇)alkylcarbonyl; a benzoyl; or a benzylcarbonyl;

- R₈ represents a hydrogen; a (C₁-C₇)alkyl; a phenyl; or a benzyl;

- R₉ and R₁₀ each independently represent hydrogen; a (C₁-C₇)alkyl; a (C₁-C₇)polyfluoroalkyl; a (C₂-C₇)alkenyl; a (C₃-C₇)cycloalkyl, optionally substituted by a hydroxy (C₁-C₄)alkyl; a pyridyl; a phenyl; a thienyl; a furyl; or alternatively R₉ and R₁₀ form, with the nitrogen atom to which they are bonded, a heterocyclic group chosen from the pyrrolidine, piperidine or piperazine groups, which are unsubstituted or substituted by (C₁-C₄)alkyls and the (C₄-C₇)azacycloalkyl groups;

- W represents a -CH₂- or -SO₂- group;

- Cy forms, with the carbon to which it is bonded, a non-aromatic, saturated or unsaturated C₃-C₁₂ hydrocarbon ring which is optionally condensed or substituted by one or a number of (C₁-C₇)alkyl groups, it being possible for the said groups to substitute the same carbon atom one or a number of times, or by a C₃-C₆ spirocycloalkyl;

- T represents a (C₁-C₄)alkylene which is optionally interrupted by a (C₃-C₆)cycloalkylene, the said alkylenes optionally being substituted one or a number of times on the same carbon atom by a (C₁-C₃)alkyl; or alternatively T represents a direct bond;

- Z represents an -NR₁₁R₁₂ group; ⁻NR₁₁R₁₂(C₁-C₄)-alkyl (A⁻), (A⁻) being an anion, preferably Cl⁻, Br⁻, I⁻ or CH₃SO₄⁻; -N(O)R₁₁R₁₂; a -COOR₁₁ group; an -NR₁₁COR₁₂ group; a benzyloxycarbonylamino; a -CONR₁₁R₁₂ group; it being understood that when T represents a methylene or a direct bond, Z cannot be -NR₁₁R₁₂ ; ⁻NR₁₁R₁₂(C₁-C₄)alkyl ; -N(O)R₁₁R₁₂ ; -NR₁₁COR₁₂ ; a benzyloxycarbonyl-amino;

- R₁₁ and R₁₂ each independently represent hydrogen; a (C₁-C₇)alkyl; a (C₁-C₄)alkoxy; a (C₃-C₇)cycloalkyl; a phenyl; a (C₁-C₃)alkylenecycloalkyl, in which the cycloalkyl is C₃-C₇, or a (C₁-C₃)alkylenepheryl, it being possible for the said groups optionally to be mono- or polysubstituted by R₁₃ ;

or alternatively R₁₁ and R₁₂ optionally form, with the nitrogen atom to which they are bonded, a heterocycle chosen from azetidine, pyrrolidine, piperidine, piperazine, piperazinone, morpholine, morpholinone, thiomorpholine and hexahydroazepine heterocycles, which heterocycle is optionally mono- or polysubstituted by R₁₃; or a thiomorpholine 1,1-dioxide or a thiomorpholine 1-oxide ; or alternatively R₁₂ represents a pyrrolidone or a piperidone ;

- R₁₃ represents a hydroxyl group; a (C₁-C₄)alkyl; a (C₁-C₄)alkoxy; a mercapto; a (C₁-C₄)alkylthio; a (C₁-C₄)alkylsulphanyl; a (C₁-C₄)alkylsulphonyl; a benzyloxy; a hydroxyalkyloxy; an NR₁₄R₁₅ group in which R₁₄ and R₁₅ each independently represent hydrogen or a (C₁-C₄)alkyl or a (C₁-C₄)alkyloxycarbonyl or a benzyloxycarbonyl; a carboxyl; a (C₁-

C₄)alkyloxycarbonyl ; a phenoxycarbonyl; a benzyloxycarbonyl; a carbamoyl; an amidino; a guanidino; an imidazolyl; a thienyl; a pyridyl; an indolyl; or a tetrahydroisoquinolyl;


and to their salts, solvates or hydrates.

- 5 It has to be noted that the compounds of formula (I) in which R₃ and R₄ are hydrogen are known compounds and that the compounds in which -O-T-Z is



are not stable and thus do not belong to the invention.

Among these compounds, are preferred those of following formula (Ia) :



10

in which :

- R₁ to R₄, W, T and Cy are as defined above for the compounds of formula (I);
 - Z_a represents an -NR₁₁R₁₂ group; -⁺NR₁₁R₁₂(C₁-C₄)-alkyl (A⁻), (A⁻) being an anion, preferably Cl⁻, Br⁻, I⁻ or CH₃SO₄⁻; -N(O)R₁₁R₁₂; a -COOR₁₁ group; an -NR₁₁COR₁₂ group; a benzyloxycarbonylamino; a -CONR₁₁R₁₂ group;
 - R₁₁ and R₁₂ each independently represent hydrogen; a (C₁-C₇)alkyl; a (C₁-C₄)alkoxy; a (C₃-C₇)cycloalkyl; a phenyl; a (C₁-C₃)alkylenecycloalkyl, in which the cycloalkyl is C₃-C₇, or a (C₁-C₃)alkylenepheryl, it being possible for the said groups optionally to be mono- or polysubstituted by R₁₃ ;
 - or alternatively R₁₁ and R₁₂ optionally form, with the nitrogen atom to which they are bonded, a heterocycle chosen from azetidine, pyrrolidine, piperidine, piperazine, piperazinone, morpholine, morpholinone, thiomorpholine and hexahydroazepine heterocycles, which heterocycle is optionally mono- or polysubstituted by R₁₃; or a thiomorpholine 1,1-dioxide or a thiomorpholine 1-oxide ;
 - R₁₃ represents a hydroxyl group; a (C₁-C₄)alkoxy; a thiol; a (C₁-C₄)alkylthio; a (C₁-C₄)alkylsulphanyl; a (C₁-C₄)alkylsulphonyl; an -NR₁₄R₁₅ group in which R₁₄ and R₁₅ each independently represent hydrogen or a (C₁-
- 15
- 20
- 25

C₄)alkyl ; a carboxyl; a carbamoyl; an amidino; a guanidino; an imidazolyl; a thienyl; a pyridyl; an indolyl; or a tetrahydroisoquinolyl; and to their salts.

5 The solvates and hydrates of the compounds of above formula (Ia) are also preferred.

In the compounds of formula (Ia), when R represents a methylene or a direct bond, Z cannot be -NR₁₁R₁₂; -⁺NR₁₁R₁₂(C₁-C₄)alkyl ; -N(O)R₁₁R₁₂ ; -NR₁₁COR₁₂; a benzyloxycarbonylamino.

10 According to the present invention, "(C₁-C₇)alkyl" or "(C₁-C₆)alkyl" is understood to mean a straight or branched alkyl having 1 to 7 carbon atoms or 1 to 6 carbon atoms respectively.

The non-aromatic C₃-C₁₂ hydrocarbon rings comprise optionally terpenic, saturated or unsaturated, condensed or bridged, mono- or polycyclic radicals. These radicals are optionally mono- or polysubstituted by a (C₁-C₄)alkyl. The
15 monocyclic radicals include cycloalkyls, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and cyclododecyl. The polycyclic radicals include, for example, norbornane, adamantane, hexahydroindane, norbornene, dihydrophenalene, bicyclo[2.2.1]heptane, bicyclo[3.3.1] nonane or tricyclo[5.2.1.0^{2,6}]decane.

20 The constituent phenyl group of the R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁ and R₁₂ substituents can be unsubstituted, mono- or disubstituted by a (C₁-C₇)alkyl, preferably methyl, a trifluoromethyl, a (C₁-C₇)alkoxy, preferably methoxy or ethoxy, or a halogen or trisubstituted by a (C₁-C₇)alkyl, a (C₁-C₇)alkoxy or a halogen.

25 According to the present invention, halogen is understood to mean an atom chosen from fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.

When a compound according to the invention has one or more asymmetric carbons, the optical isomers of this compound form an integral part of the invention.

30 When a compound according to the invention exhibits stereoisomerism, for example of axial-equatorial type or Z-E, the invention comprises all the stereoisomers of this compound.

The salts of the compounds of formula (I) according to the present invention comprise those with inorganic or organic acids which make possible suitable separation or crystallization of the compounds of formula (I), such as picric acid, oxalic acid or an optically active acid, for example a tartaric acid, a dibenzoyltartaric
35 acid, a mandelic acid or a camphorsulphonic acid, and those which

or a (C₁-C₃)alkylenephenyl, it being possible for the said groups optionally to be mono- or polysubstituted by R₁₃ ;

or alternatively R₁₁ and R₁₂ optionally form, with
5 the nitrogen atom to which they are bonded, a heterocycle chosen from azetidine, pyrrolidine, piperidine, piperazine, piperazinone, morpholine, morpholinone, thiomorpholine and hexahydroazepine heterocycles, which heterocycle is optionally mono- or polysubstituted by
10 R₁₃; or a thiomorpholine 1,1-dioxide or a thiomorpholine 1-oxide ;

- R₁₃ represents a hydroxyl group; a (C₁-C₄)alkoxy; a thiol; a (C₁-C₄)alkylthio; a (C₁-C₄)alkylsulphonyl; a (C₁-C₄)alkylsulphonyl; an -NR₁₄R₁₅ group in which R₁₄ and
15 R₁₅ each independently represent hydrogen or a (C₁-C₄)alkyl ; a carboxyl; a carbamoyl; an amidino; a guanidino; an imidazolyl; a thienyl; a pyridyl; an indolyl; or a tetrahydroisoquinolyl; and to their salts.

20 The solvates and hydrates of the compounds of above formula (Ia) are also preferred.

In the compounds of formula (Ia), when R represents a methylene or a direct bond, Z cannot be -NR₁₁R₁₂; -⁺NR₁₁R₁₂(C₁-C₄)alkyl ; -N(O)R₁₁R₁₂ ; -NR₁₁COR₁₂; a (C₁-
25 C₄)alkyloxycarbonylamino; a benzyloxycarbonylamino.

According to the present invention, "(C₁-C₇)alkyl" or "(C₁-C₆)alkyl" is understood to mean a straight or branched alkyl having 1 to 7 carbon atoms or 1 to 6 carbon atoms respectively.

30 The non-aromatic C₃-C₁₂ hydrocarbon rings comprise optionally terpenic, saturated or unsaturated, condensed or bridged, mono- or polycyclic radicals. These radicals are optionally mono- or polysubstituted by a (C₁-C₄)alkyl. The monocyclic radicals include
35 cycloalkyls, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and

cyclododecyl. The polycyclic radicals include, for example, norbornane, adamantane, hexahydroindane, norbornene, dihydrophenalene, bicyclo[2.2.1]heptane, bicyclo[3.3.1]nonane or tricyclo[5.2.1.0^{2,6}]decane.

5 The constituent phenyl group of the R₁, R₂, R₃, R₄,
R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁ and R₁₂ substituents can be
unsubstituted, mono- or disubstituted by a (C₁-C₇)alkyl,
preferably methyl, a trifluoromethyl, a (C₁-C₇)alkoxy,
preferably methoxy or ethoxy, or a halogen or
10 trisubstituted by a (C₁-C₇)alkyl, a (C₁-C₇)alkoxy or a
halogen.

According to the present invention, halogen is understood to mean an atom chosen from fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.

When a compound according to the invention has one or more asymmetric carbons, the optical isomers of this compound form an integral part of the invention.

When a compound according to the invention exhibits
20 stereoisomerism, for example of axial-equatorial type or
Z-E, the invention comprises all the stereoisomers of
this compound.

The salts of the compounds of formula (I) according to the present invention comprise those with inorganic or organic acids which make possible suitable separation or crystallization of the compounds of formula (I), such as picric acid, oxalic acid or an optically active acid, for example a tartaric acid, a dibenzoyltartaric acid, a mandelic acid or a camphorsulphonic acid, and those which form physiologically acceptable salts, such as the hydrochloride, the hydrobromide, the sulphate, the hydrogensulphate, the dihydrogenphosphate, the maleate, the fumarate, the 2-naphthalenesulphonate or the para-toluenesulphonate.

35 The salts of the compounds of formula (I) also
comprise salts with organic or inorganic bases, for

example the salts of alkali metals or alkaline-earth metals, such as the sodium, potassium or calcium salts, the sodium and potassium salts being preferred, or with an amine, such as trometamol, or alternatively the salts
5 of arginine, of lysine or of any physiologically acceptable amine.

The functional groups optionally present in the molecule of the compounds of formula (I) and the reaction intermediates can be protected, either in a permanent
10 form or in a temporary form, by protective groups which provide for unambiguous synthesis of the expected compounds.

Temporary protective group for amines, alcohols, phenols, thiols or carboxylic acids is understood to mean
15 the protective groups such as those described in Protective Groups in Organic Synthesis, Greene T.W. and Wuts P.G.M., published by John Wiley and Sons, 1991 and in Protective Groups, Kocienski P.J., 1994, Georg Thieme Verlag.

Mention may be made, for example, of the temporary protective groups for amines : benzyls, carbamates, (such as *tert*-butyloxycarbonyl, which can be cleaved in acid medium, or benzyloxycarbonyl, which can be cleaved by hydrogenolysis), for carboxylic acids (alkyl esters, such
25 as methyl, ethyl or *tert*-butyl esters, which can be hydrolysed in basic or acid medium, or benzyl esters, which can be hydrogenolysed), for alcohols or for phenols such as tetrahydropyranyl, methoxymethyl or methylethoxymethyl, *tert*-butyl and benzyl ethers) and
30 reference may be made to the well known general methods described in Protective Groups, cited above.

Preference will be given according to the present invention to the temporary protective groups which can be cleaved in acid medium or in neutral medium by
35 hydrogenolysis.

0905400.01498
862410 00675000

The permanent protective groups are those which are stable under the cleavage conditions cited above and which are capable of being present in the final products. Such O-protective or N-protective groups are composed of (C₁-C₇)alkyl or phenyl groups. The permanent N-protective groups also include (C₁-C₅)alkanoyl groups and aroyl groups, such as benzoyl.

The compounds (I) can contain precursor groups of other functional groups which are generated subsequently in one or a number of other stages.

The compounds of formula (I) wherein the various polar functions, in particular salifiable functions which improve solubility and/or disponibility in water are preferably carried by the -T-Z groups.


15 The compounds of formula (I) in which the R₁ substituent is in the 5-position of the indolin-2-one and in which R₂ represents hydrogen are preferred compounds.

The compounds of formula (I) in which R₁ is in the 5-position and represents a chlorine atom or an ethoxy group and R₂ represents hydrogen are also preferred.

The compounds of formula (I) in which R₃ represents hydrogen or a methoxy and R₄ represents a methoxy, diethylureido, *tert*-amylcarbamoyl and *tert*-butylcarbamoyl group in the 4-position of the benzene ring are preferred compounds. Among these compounds, those in which R₃ is in the 2-position are preferred.


The compounds of formula (I) in which Cy represents a cyclohexane and the -O-T-Z group is in the 4-position of the said cyclohexane with respect to the spiro carbon are also preferred.

The compounds of formula:



in which R_1 , R_3 , R_4 , W , T and Z are as defined for (I), and their salts, solvates or hydrates are particularly preferred.


5 The compounds of formula:



in which R_1 , R_3 , R_4 , T and Z are as defined for (I), and their salts, solvates or hydrates are more particularly preferred.


10

The compounds of formula:



in which R_1 , R_3 and R_4 are as defined for (I), T represents a (C_1-C_3) alkylene and Z represents an amino group, a 2-hydroxyethylamino, a 2-(2-hydroxy)ethyloxy-ethylamino, a morpholinyl or a carboxylic group, and their salts, solvates or hydrates are very particularly preferred.

The compounds of formula:



in which R_1 , T and Z are as defined for (I), and their salts, solvates or hydrates are more particularly preferred.

The compounds of formulae (I.1), (I.2), (I.3) and (I.4) in which Z has the meaning of Za and the salts thereof are also preferred compounds. It is the same for the solvates and hydrates of these compounds.

The compounds of formulae (I.1), (I.2), (I.3) and (I.4) in which :

- R₁ represents a chlorine atom or an ethoxy group,
- T represents a (C₁-C₃)alkylene and Z represents an amino group, a 2-hydroxyethylamino, a 2-(2-hydroxy)ethyloxyethylamino, a morpholinyl or a carboxylic group, are particularly preferred.

The compounds of formulae (I.1), (I.2), (I.3) in which :

- R₁ represents a chlorine atom or an ethoxy group;
- R₃ represents hydrogen or a methoxy group;
- R₄ represents a methoxy, diethylureido, *tert*-amylcarbamoyl and *tert*-butylcarbamoyl, are also preferred.

Among these compounds, those in which T represents a (C₁-C₃)alkylene and Z represents an amino group, a 2-hydroxyethylamino, a 2-(2-hydroxy)ethyloxyethylamino, a morpholinyl or a carboxylic group are preferred.

The products of formula (I), (I.1), (I.2), (I.3) and (I.4) in which Cy represents a cyclohexane and for which the O-T-Z group is in the 4-position of the said cyclohexane with respect to the spiro carbon, in particular the compounds below:

*5-chloro-3-spiro-[4-(2-morpholinoethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl]indolin-2-one;

*5-ethoxy-3-spiro-[4-(2-aminoethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl]indolin-2-one;

*5-ethoxy-3-spiro-[4-(2-(N-methyl-N-(2-hydroxyethyl)amino)ethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl]indolin-2-one;

*5-ethoxy-1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzenesulphonyl]-3-spiro-[4-(2-morpholinoethyloxy)-cyclohexane]indolin-2-one;

*5-ethoxy-3-spiro-(4-carboxymethyloxy)cyclohexane)-1-(4-N-tert-butylcarbamoyl-2-methoxybenzenesulphonyl)-indolin-2-one;

*5-ethoxy-3-spiro-[4-(2-morpholinoethyloxy)cyclohexane]-1-[4-(N-tert-amylcarbamoyl)-2-methoxybenzenesulphonyl]indolin-2-one;

*5-ethoxy-3-spiro-[4-(2-carboxyethyloxy)cyclohexane]-1-[4-(N-tert-amylcarbamoyl)-2-methoxybenzenesulphonyl]indolin-2-one;

*5-ethoxy-1-[4-(N',N'-diethylureido)-2-methoxybenzenesulphonyl]-3-spiro-[4-(2-dimethylaminoethyloxy)-cyclohexane]indolin-2-one;

*5-Ethoxy-3-spiro-[4-(2-(4-ethoxypiperidino)-ethyloxy)cyclohexane]-1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

*5-Ethoxy-3-spiro-[4-(2-glycylaminoethyloxy)-cyclohexane]-1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

*5-Ethoxy-3-spiro-[4-(2-(N,N-diméthylglycylamino)-ethyloxy)cyclohexane]-1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

*5-Chloro-3-spiro-[4-(N-(3-dimethylaminopropyl)-carbamoylmethyloxy)cyclohexane]-1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

*5-Ethoxy-3-spiro-[4-(2-(4-dimethylaminobutyrylamino)ethyloxy)cyclohexane]-1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;


*5-Ethoxy-3-spiro-[4-(2-(2-hydroxyethylamino)-ethyloxy)cyclohexane]-1-[4-(N-tert-butylcarbamoyl)-2-méthoxybenzenesulfonyl]indolin-2-one ;

*5-Ethoxy-3-spiro-[4-(2-(-L-γ-glutamylamino)-ethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;


5 *5-Ethoxy-3-spiro-[4-(2-(-L-pyroglutamylamino)-ethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

10 *5-Ethoxy-3-spiro-[4-(2-(2-(2-hydroxyethyloxy)-ethylamino)ethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;
and their pharmaceutically acceptable salts, solvates or hydrates are very particularly preferred, being particularly suited to use in pharmaceutical formulations.

The compounds according to the invention can be prepared according to Scheme 1 below.




SCHEME 1



Another subject of the present invention is a process for the preparation of the compounds of formula (I) according to the invention, characterized in that:

(1) either a compound of formula:

5




in which R_1 , R_2 , R_3 , R_4 , W , Cy and T are as defined for (I) and in which X is a nucleofuge group, such as a halogen, preferably bromine, chlorine or iodine, or a sulphonic acid derivative, such as tosyloxy or mesyloxy, is reacted with a derivative of formula ZH (1) in which Z is as defined for (I) containing a nucleophilic group capable of displacing X , for example a primary or secondary amine, preferably a secondary amine, in polar solvents, such as dimethylformamide, tetrahydrofuran or acetonitrile, at temperatures of between 0° and $120^\circ C$, or alternatively X represents a reducible group, such as an azido, which is subsequently reduced to amino;

15


(2) or, when $Z = -COOH$, a compound of formula:

20




in which R_1 , R_2 , W , R_3 , R_4 and Cy are as defined for (I) and T' represents $T-CH_2-$, is reacted with an oxidizing agent, such as chromium oxide in an acid solvent, such as dilute acetic acid at a temperature of between 0° and $100^\circ C$, alkali metal dichromates or alkali metal or alkaline-earth metal permanganates;

(3) or a compound of formula:




in which R_1 , R_2 , Cy , T and Z are as defined for (I), is reacted with a compound of formula:




in which W , R_3 and R_4 are as defined for (I) and Hal represents a halogen atom, in the presence of a metal hydride, such as, for example, sodium hydride, or an alkali metal alkoxide, such as, for example, potassium *tert*-butoxide, at temperatures of between -40° and $25^\circ C$, in an anhydrous solvent such as tetrahydrofuran;

(4) or, when $Z = -COOH$, a compound of formula:




in which R_1 , R_2 and Cy are as defined above for (I) and T' represents $T-CH_2$, is reacted with an oxidizing agent described above for the conversion of (II'A) to (I), then the acid thus obtained of formula:

5



in which R_1 , R_2 , Cy and T are as defined above for (I), is subsequently optionally protected by a protective group for the carboxylic acid, in order to obtain the intermediate of formula:

10




in which R_1 , R_2 , Cy and T are as defined for (I) and P represents a protective group chosen from an alkyl, such as a *tert*-butyl or a benzyl, and, finally, this compound (II''BP) is subjected to the action of a derivative of formula (2) in order to obtain, after deprotection, a compound (I); which is optionally converted to one of its salts according to techniques well known to the person skilled in the art.

15

20

The compounds (II A) and (II B) can be prepared from the compounds (III) according to the following Scheme 2:

SCHEME 2



5

The compounds (II A) can be prepared from the indolin-2-one (III) with a benzenesulphonyl halide, when W represents an -SO₂- group, or with a benzyl halide, when W represents a -CH₂- group, in an anhydrous solvent, such as dimethylformamide or tetrahydrofuran, in the presence of a metal hydride, such as sodium hydride, or of an alkali metal alkoxide, such as, for example, potassium *tert*-butoxide, at temperatures of between -40° and 25°C.

15 The compounds (II A) can also be prepared from the alcohols (II' A) according to known general methods. Mention may be made, for example, of the triphenylphosphine/carbon tetrachloride system according to Angew. Chem. Int. Ed., 1975, 14, 801 or the triphenylphosphine/C(Hal)₄ system, in which Hal represents a halogen, in the presence of pyridine according to Carbohyd. Res., 1978, 61, 511 or by reaction with an aryl- or alkylsulphonyl halide in the presence of a base in an inert solvent. The X groups can be exchanged: for example, a sulphonate group can be converted to a halide, such as an iodine derivative, by reaction with an alkali metal iodide, such as sodium iodide, according to J. Chem. Soc., 1949, 326. When X represents a halogen, the halide (II A) can be converted to alcohol (II' A) by substitution by a nitrate ion, which is subsequently

20

25

30

reduced in the presence of a metal catalyst, such as palladium-on-charcoal, according to the method described in J. Med. Chem., 1995, 38, 130-136.


The compounds of formula (II' A) can also be prepared from the corresponding indolin-2-ones (III') by reaction with the reactants (2) under the conditions already described for the conversion of the compounds (III) to (II A). The alcohol group of (III') will be temporarily protected (compounds III' P), for example by a protective group, such as methyl or tetrahydropyranyl, according to EP 636,608.

The compounds (II B) can be prepared from the indolin-2-one (III) by substitution of the nucleofuge group X by a ZH derivative (1), such as, for example, a primary or secondary amine, in polar solvents, such as dimethylformamide, tetrahydrofuran or acetonitrile, at temperatures of between 0° and 120°C, according to the nature of the nucleophile and of the nucleofuge.


The compounds (II B) for which -T-Z represents
20 -T-COOH are prepared from an alcohol (III') in which T'
represents T-CH₂- by oxidizing the alcohol (III')
according to the conditions described for the conversion
of (II' A) to (I).

The compounds (III) are novel and form part of the
25 invention. They can be prepared according to the reaction
Scheme 3 below:

SCHEME 3



5 Thus, the indolin-2-ones (III) can be obtained by
reduction of the acetals (IV) under mild conditions, for
example according to the method described in J. Org.
Chem., 1987, 52, 2594-2596, by the action of zinc
borohydride in the presence of trimethylsilyl chloride in
10 ethers or chlorinated solvents, such as, for example,
dichloromethane, or by the action of the dimethyl
sulphide·BH₃ complex in the presence of trimethylsilyl
triflate in ethers or dichloromethane according to the
method described in J. Org. Chem., 1993, 58, 6756-6765,
15 or from the alcohols (III'):




in which R_1 , R_2 , Cy and T are as defined for (I), according to the methods cited above for the conversion of (II' A) to (II A).

The acetals (IV) are prepared by well known reactions, for example from a ketone (V) with an alcohol by acid catalysis in dehydrating medium. The preparation can be carried out by azeotropic removal of water or in the presence of molecular sieves, according to Synthesis, 1972, 419.

The ketones (V) can be prepared from the corresponding secondary alcohols (VI) according to numerous methods well known to the person skilled in the art involving, for example, oxidizing agents, such as chromium oxide in acetic acid medium or chromium oxide complexes, such as pyridinium chlorochromate, in inert solvents, such as ethyl acetate or dichloromethane, or alternatively by hydrolysis of the acetals (IV').

The alcohols (VI) can be obtained from the corresponding compounds in which the hydroxyl group is protected, for example by a methoxymethyl or tetrahydropyranyl group. These compounds are described in EP 636,608 or are obtained similarly. The compounds thus protected of formula:




(XI)

are subjected to an acid hydrolysis in an alcohol, such as methanol or ethanol, or in an ether, such as tetrahydrofuran, at temperatures of between -5° and 70°C .

The compounds (III') can be prepared according to Scheme 4 below:

SCHEME 4



As for the preparation of the compounds (III) from the acetals (IV), the compounds (III') can be prepared from a cyclic acetal (IV'), such as a dioxolane, which is obtained from a hydrazide (VII).

A halide (III) can also be converted to (III') according to the methods already cited for the conversion of the compounds (II A) to compounds (II' A).

Unlike, and as for the conversion of the compounds (II'A) to compounds (II A) according to the methods already cited, the alcohols (III') can also be converted to compounds (III) wherein X is a nucleofuge group such as alkyl or benzenesulphonate by reaction with an alkyl halide or a phenylsulphonyl halide in inert solvents in the presence of a tertiary amine or in pyridine.

The compounds (III') can be converted to compounds (III'P) in which the alcohol group is protected as indicated above. The compounds (III'P) can also be converted to compounds (II A) wherein X is a temporary
5 protected alcohol according to reactions previously described.


The compounds (IV') in which T is at least equal to -CH₂CH₂- can be prepared from the ketones (V) by reaction with a diol HO-T-OH according to the conditions mentioned
10 for the conversion of (V) to (IV). The compounds (IV') can also be obtained directly from the corresponding hydrazides (VII) by a Brunner reaction described by Moore R. F. et al., J. Chem. Soc., 1951, 3475-3478, for example by heating in solvents, such as quinoline, in the
15 presence of a metal or alkaline-earth metal oxide, such as calcium oxide. The reaction can also be carried out by heating in inert solvents, such as tetralin, naphthalene or 1,2,3,4-tetramethylbenzene, according to the method described by Wolff J. et al., Tetrahedron, 1986, 42,
20 (15), 4267-4272, starting with a lithium salt prepared beforehand in an inert solvent, such as tetrahydrofuran, at low temperature.

These phenylhydrazide derivatives (VII) can be obtained from a phenylhydrazine (IX), which are known
25 compounds or compounds prepared according to known methods, and from derivatives of the carboxylic acids (VIII), such as the esters, chlorides or mixed anhydrides obtained by reaction of an alkyl chloroformate, preferably isobutyl chloroformate, in the presence of a
30 base according to conventional methods well known to the person skilled in the art. The acids (VIII) are known or prepared according to known methods.

An alternative for the synthesis of the compounds (I) in which T represents -CH₂- and Z represents a
35 -COOZ₁ group in which Z₁ represents hydrogen, a (C₁-

005100-01398
B64T40-005100

C₃)alkyl or a benzyl comprises the use of an alcohol of formula:




5 in which R₁, R₂, R₃, R₄, W and Cy are as defined for (I), which are known products or products prepared according to EP 636,609, which are alkylated with a powerful alkylating agent, such as a trifluoromethanesulphonate of formula CF₃SO₂O-CH₂-COOAlk (3) generated in situ by
 10 reaction of silver triflate with the corresponding halogenated derivative in which Alk represents a (C₁-C₄)alkyl, in halogenated solvents, such as dichloromethane or carbon tetrachloride, in the presence of a base, such as 2,6-di-*tert*-butylpyridine, according
 15 to the method described for alkyl trifluoromethanesulphonates in Carbohydrate Research, 1975, 44, C₅-C₇.

The ester thus obtained can be exchanged or cleaved under the general conditions already mentioned.

20 The alcohols (II C) can be prepared according to the following Scheme 5:

SCHEME 5



The alcohols (II C) can be prepared from the
 5 protected compounds (X) by deprotection under the same
 conditions as for the conversion of the compounds (XI) to
 compounds (VI).


The compounds (X) are obtained from the compounds
 (XI) according to the method described in EP 636,608 with
 10 the halides (2) according to the conditions already
 described for the conversion of the compounds (II B) to
 (I) and the compounds (III) to (II A).

A compound of formula (I) can also be converted to
 another compound of formula (I) carrying a polyfunc-
 15 tional residue as defined for Z, in particular for

-NR₁₁COR₁₂ or for -CONR₁₁R₁₂, the reaction being carried out according to known methods for peptide synthesis described, for example, by Bodansky M. in Principles of Peptide Synthesis 2nd ed., 1993 and Bodansky M. in Peptide Chemistry, Springer Verlag; thus, these methods make it possible to avoid the racemization of asymmetric centres possibly carried by the amino acids.

The reactants ZH of formula (1) are commercially available or prepared according to known methods.

10 The derivatives of formula (2):



are also prepared according to known methods. In particular, the benzenesulphonyl halides in which W = -SO₂- and R₃ and R₄ are as defined above for (I) are prepared by known methods. Thus, for example, 4-dimethylaminobenzenesulphonyl chloride is prepared according to Sukenik C. N. et al., J. Am. Chem. Soc., 1977, 99, 851-858. More generally, benzenesulphonyl halides substituted by a dimethylamino group are known or prepared by known methods; 4-benzyloxybenzenesulphonyl chloride is prepared according to EP 229,566.

25 The alkoxybenzenesulphonyl chloride is prepared from the sodium alkoxybenzenesulphonate, itself prepared by reacting an alkyl halide with sodium hydroxybenzenesulphonate.

The benzenesulphonyl halides are obtained according to Col. Czechoslov. Chem. Commun., 1984, 49, 1184, from the aniline derivatives substituted by the same group, the said aniline derivatives themselves being obtained from the corresponding nitro derivatives.

30 The benzenesulphonyl halide (2) in which the substituent in the 4-position represents an -NHCON(CH₂CH₃)₂ group can be prepared by reacting

chlorosulphonic acid with N',N'-diethyl-N-phenylurea, itself obtained by reacting aniline with diethylcarbamoyl chloride.

In the case where R₃ or R₄ represent an N-substituted carbamoyl, it is possible to condense a compound (2) in which R₃ is a carboxylic acid precursor, such as N-benzylcarbamoyl, to deprotect the protective group by hydrogenolysis and then to condense with the desired amine or alternatively directly to prepare (2) in which R₃ has the expected value. The reaction is generally carried out from the correctly chosen anilines, themselves being obtained by reduction of the corresponding nitro derivatives.

The anilines are diazotized under conventional conditions by nitrous acid and reacted with SO₂ in the presence of cupric chloride according to J. Heterocyclic Chem., 1986, 23, 1253.

The benzyl halides in which W represents -CH₂- are known or prepared according to known methods. Mention may be made, for example, of J. V. Rajanbabu, J. Org. Chem., 1986, 51, 1704-1712 and the publications cited in EP 636,609.

The halomethylbenzene derivatives can generally be prepared by reacting N-halosuccinimides with the corresponding methylbenzene derivatives and according to EP 229,566.

The reaction is carried out in a solvent, such as carbon tetrachloride, in the presence of dibenzoyl peroxide. It is also possible to prepare a halomethylbenzene derivative from a corresponding hydroxymethylbenzene derivative by reacting with phosphorus tribromide in ether or by reacting with thionyl chloride.

The compounds (3) are obtained from an alkyl iodoacetate and from a trifluoromethanesulphonic acid salt, such as the silver salt, according to Chem. Reviews, 1977, 77.

5

1

2

3

3

5

10

15

20

30

+

35

This type of V₂ antagonist molecules with an
30 aquaretic profile has a wide range of therapeutic
indications and constitutes a major innovation in the
treatments of cardiac insufficiency, hyponatraemias,
water disorders, water retentions, and the like. This
type of compound can advantageously replace conventional
35 diuretics in all pathologies where they are recommended
in man and in animals. It is also possible, with such

formulations. For topical application, the compounds according to the invention can be used in creams, ointments, lotions or eye washes.

In order to obtain the desired prophylactic or therapeutic effect, the dose of active principle can vary between 0.01 and 50 mg per kg of body weight per day.

Each unit dose can contain from 0.5 to 1000 mg, preferably from 1 to 500 mg, of active ingredients in combination with a pharmaceutical vehicle. This unit dose can be administered 1 to 5 times per day so as to administer a daily dosage of 0.5 to 5000 mg and preferably of 1 to 2500 mg.

When a solid composition is prepared in the form of tablets, the main active ingredient is mixed with a pharmaceutical vehicle, such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like. The tablets can be coated with sucrose, with a cellulose derivative or with other appropriate materials or alternatively they can be treated so that they have a sustained or delayed activity and so that they continuously release a predetermined amount of active principle.

A preparation in gelatin capsules is obtained by mixing the active ingredient with a diluent and by pouring the mixture obtained into soft or hard gelatin capsules.

A preparation in the form of a syrup or an elixir or for administration in the form of drops can contain the active ingredient in conjunction with a sweetener, preferably a calorie-free sweetener, methylparaben and propylparaben as antiseptic as well as an agent which gives taste and an appropriate dye.

Water-dispersible powders or granules can contain the active ingredient as a mixture with dispersing agents or wetting agents, or suspending agents, such as

polyvinylpyrrolidone, as well as with sweeteners or taste correctors.

For rectal administration, recourse is had to suppositories which are prepared with binders which melt
5 at rectal temperature, for example 'cocoa butter or poly(ethylene glycol)s.

For parenteral administration, use is made of aqueous suspensions, isotonic saline solutions or sterile injectable solutions which contain pharmacologically
10 compatible dispersing and/or wetting agents, for example propylene glycol or butylene glycol.

The active principle can also be formulated in the form of microcapsules, optionally with one or a number of vehicles or additives, or alternatively with matrices,
15 such as a polymer or a cyclodextrin (patch or sustained-release compositions).

The compositions according to the invention can be used in the treatment or the prevention of different vasopressin-dependent or oxytocin-dependent complaints
20 and in dysfunctions of vasopressin or oxytocin secretion, cardiovascular complaints, such as hypertension, pulmonary hypertension, cardiac insufficiency, circulatory insufficiency, myocardial infarction, atherosclerosis or coronary vasospasm, in particular in
25 smokers, unstable anginas and PTCA (percutaneous transluminal coronary angioplasty), cardiac ischaemia, disturbances of haemostasis, in particular haemophilia, or von Willebrand's syndrome; complaints of the central nervous system, migraine, cerebral vasospasm, cerebral
30 haemorrhage, cerebral oedemas, depression, anxiety, bulimia, psychotic states or memory disorders, for example; renopathies and renal dysfunctions, such as oedemas, renal vasospasm, renal cortex necrosis, nephrotic syndrome, hyponatraemia, hypokalaemia,
35 diabetes, Schwartz-Bartter syndrome or renal lithiasis; complaints of the gastric system, such as gastric

000400.0438
000400.0438

vasospasm, hepatocirrhosis, ulcers, the pathology of vomiting, for example nausea, including the nausea due to chemotherapy, travel sickness, or alternatively the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), diabetes insipidus and enuresis; complaints of the hepatic system, such as cirrheses of the liver; abdominal ascites and all the disorders inducing abnormal water retention, suprarenal disorders (Cushing's disease) and in particular hypercorticism and hyperaldosteronaemia. The compositions according to the invention can also be used in the treatment of disorders of sexual behaviour, in the weight excess and obesity by favourably replacing the usual diuretics already used for this indication. In woman, the compositions according to the invention can be used for treating dysmenorrhoea or premature labour. The compositions according to the invention can also be used in the treatment of small-cell lung cancers, hyponatraemic encephalopathies, Raynaud's disease, Menière's syndrome, pulmonary syndrome, glaucoma and the prevention of cataracts and in postoperative treatments, in particular after abdominal, cardiac or hemorrhagic surgery.

The compositions of the present invention can contain, in addition to the products of formula (I) above or their pharmaceutically acceptable salts, solvates or hydrates, other active principles which can be used in the treatment of the disorders or diseases indicated above.

Thus, another subject of the present invention is pharmaceutical compositions containing a number of active principles in combination, one of which is a compound according to the invention.

Thus, according to the present invention, pharmaceutical compositions can be prepared which contain a compound according to the invention in combination with a compound which acts on the renin-angiotensin system, such

0054900.04798

as an inhibitor of the converting enzyme, an angiotensin II antagonist or a renin inhibitor. A compound according to the invention can also be combined, for example, with a peripheral vasodilator, a calcium inhibitor, a β -blocker, an α_1 -blocker or diuretic. Such compositions will be useful in particular in the treatment of hypertension or heart failure. Two compounds according to the invention can also be combined: a specific antagonist of the V_1 receptor with a specific antagonist of oxytocin or a V_1 antagonist and a V_2 antagonist or a V_2 antagonist and V_1 agonist.

The compositions of the present invention advantageously contain a product of formula (I.1), (I.2), (I.3) or (I.4) above or one of its pharmaceutically acceptable salts, solvates or hydrates. Each of these compounds can also be combined with a specific angiotensin II antagonist, preferably with irbesartan.

These combinations will make it possible to reinforce the therapeutic activities of the compounds according to the invention.

The following PREPARATIONS and EXAMPLES illustrate the invention without, however, limiting it.

The nuclear magnetic resonance spectra were performed in DMSO-d6 except as otherwise mentioned at 200 MHz and the chemical shifts were expressed in ppm.

The following abbreviations are used :

s = singulet

m = multiplet

t = triplet

q = quintuplet

PREPARATION I Alcohols of formula (VI)

5-Ethoxy-3-spiro-(4-hydroxycyclohexane)indolin-2-one. Compound (VI.1)

A solution of 22 g of 5-ethoxy-3-spiro-(4-methoxy-methyloxycyclohexane)indolin-2-one, prepared according to EP 636,608 in 130 ml of methanol and 9 ml of concentrated hydrochloric acid (36%) is heated at 40° for 3 hours. The reaction mixture is cooled and the precipitate is then successively filtered off, rinsed with diethyl ether and dried to obtain the polar isomer of the expected product; M.p. = 225°C. 50 ml of water are added to the filtrate and then, successively, the methanol is evaporated, extraction is carried out with dichloromethane and the organic phases are washed with water, dried and evaporated to obtain the expected product in the form of a mixture of isomers; M.p. = 170°C.

5-Chloro-3-spiro-(4-hydroxycyclohexane)indolin-2-one. Compound (VI.2)

The preparation is carried out according to the same procedure as above, from 5-chloro-3-spiro-(4-methoxymethyloxycyclohexane)indolin-2-one prepared from 5-chloroindolin-2-one according to the method described in EP 636,608. The expected product is isolated, after extraction with dichloromethane, in the form of a mixture of isomers; M.p. = 260°C.

PREPARATION II Ketones of formula (V)

5-Ethoxy-3-spiro-(4-oxocyclohexane)indolin-2-one. Compound (V.1)

3.8 g of 5-ethoxy-3-spiro-(4-hydroxycyclohexane)indolin-2-one (VI.1) (mixture of isomers) and 5.8 ml of pyridine are dissolved in 250 ml of ethyl acetate and 6.3 g of pyridinium chlorochromate, adsorbed on 29 g of neutral alumina, are added. The reaction mixture is then stirred at 25°C for 16 hours, filtration is then carried out and the solvent is evaporated from the filtrate. 3.4 g

of the expected product are isolated after recrystallization from toluene in the presence of active charcoal; M.p. = 168°C.

5-Chloro-3-spiro-(4-oxocyclohexane)indolin-2-one.

5 Compound (V.2)

This compound is prepared according to the same procedure as for the preparation of Compound (V.1) from 5-chloro-3-spiro-(4-hydroxycyclohexane)indolin-2-one (VI.2); M.p. = 220°C.

10

PREPARATION III Acetals of formula (IV)

5-Ethoxy-3-spiro-[4,4-di(2-chloroethyloxy)-cyclohexane]indolin-2-one. Compound (IV.1)

3 g of 5-ethoxy-3-spiro-(4-oxocyclohexane)indolin-2-one (V.1) are dissolved in 30 ml of toluene and 4.6 ml of 2-chloroethanol, 20 g of 5 Å molecular sieve and 0.22 g of methanesulphonic acid are added. The reaction mixture is slowly stirred for 18 hours at 20°C, filtration is then carried out and the molecular sieve is rinsed with dichloromethane. The solvent is evaporated and the expected product is then crystallized from diethyl ether; M.p. = 170°C.

5-Ethoxy-3-spiro-[4,4-di(3-chloropropoxy)cyclohexane]indolin-2-one. Compound (IV.2)

25 The preparation is carried out according to the same procedure as for the preparation of Compound (IV.1) from the same ketone (V.1) and 3-chloropropanol; M.p. = 147°C.

5-Chloro-3-spiro-[4,4-di(2-chloroethyloxy)-cyclohexane]-indolin-2-one. Compound (IV.3)

30 The preparation is carried out according to the same procedure as for the preparation of Compound (IV.1) from Compound (V.2) and 2-chloroethanol; M.p. = 174°C.

PREPARATION IV Derivatives of formula (III)

35 5-Ethoxy-3-spiro-[4-(3-chloropropoxy)cyclohexane]-indolin-2-one (mixture of isomers). Compound (III.1)

000490 043
000490 043

2.2 ml of a 0.29M solution of zinc borohydride in diethyl ether (prepared according to the method described in Chem. Pharm. Bull., 1984, 32 (4), 1411-1415) are slowly added at 0°C to 0.55 g of acetal (IV.2) in 3 ml of dichloromethane, followed by 0.34 ml of trimethyl-chlorosilane. The reaction mixture is stirred for 16 hours at 20°C and then, successively, 10 ml of a saturated NaHCO₃ solution are added, extraction is carried out with ethyl acetate and the organic phases are washed with a saturated NaCl solution. After drying over MgSO₄ and evaporation, 0.4 g of an oil is isolated, which oil is chromatographed on silica gel, elution being carried out with an 8/2 (v/v) cyclohexane/ethyl acetate mixture. The expected product is isolated (mixture of isomers) in the form of a resin.

¹H NMR, CDCl₃, 200 MHz : 7.75 (s, 1H), 7.03 (d, 0.25H), 6.83 (d, 0.75H), 6.79-6.65 (m, 3H), 4.06-3.9 (q, 2H), 3.72-3.58 (m, 4H), 3.54-3.50 (m, 1H), 2.18-1.53 (m, 10H), 1.37 (t, 3H).

5-Ethoxy-3-spiro-[4-(2-chloroethyloxy)cyclohexane]-indolin-2-one (mixture of isomers). Compound (III.2)

The preparation is carried out according to the same procedure as for the preparation of Compound (III.1) from Compound (IV.1).

¹H NMR, CDCl₃, 200 MHz : 8 (s, 1H), 6.85-6.63 (m, 3H), 4.03-3.93 (q, 2H), 3.81-3.74 (m, 2H), 3.70-3.58 (m, 3H), 2.21-1.55 (m, 8H), 1.4 (t, 3H).

5-Chloro-3-spiro-[4-(2-chloroethyloxy)cyclohexane]-indolin-2-one (mixture of isomers). Compound (III.3)

The preparation is carried out according to the same procedure as for the preparation of Compound III.1 from Compound (IV. 3).

¹H NMR, DMSO-d₆ 200 MHz : 10.49 (s, 0.25H), 10.39 (s, 0.75H), 7.40 (s, 1H), 7.21-7.16 (d, 1H), 6.81-6.77 (d, 1H), 3.7 (m, 4H), 3.55 (m, 1H), 1.96-1.61 (m, 8H).

5-Ethoxy-3-spiro-[4-(2-tosyloxy)cyclohexane]-indolin-2-one. Compound (III.4)

17.97 g of tosyl chloride are added at 0°C to 19,25 g of compound (III'1) described in preparation X in 130 ml of pyridine. The reaction mixture is stirred at 20°C for 3 hours. The reaction mixture is poured into 650 ml of water and then stirred for 30 minutes. 28.06 g of the expected product are isolated after filtration, washings with water and drying at 40°C under vacuum in the presence of phosphoric anhydride. The product obtained from the polar isomer (III'1) melts at 152°C.

PREPARATION V Derivatives of formula (II A)

5-Ethoxy-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl]-3-spiro-[4-(2-chloroethyloxy)-cyclohexane]indolin-2-one (mixture of isomers). Compound (IIA.1)

0.29 g of potassium *tert*-butoxide is added to a solution, cooled to -60°C, of 0.75 g of chlorinated derivative (III.2) and 0.75 g of 4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl chloride in 90 ml of tetrahydrofuran. The temperature is allowed to rise to 20°C, the reaction mixture is stirred for 2 hours, 30 ml of a 15% NaCl solution are then added and, successively, extraction is carried out with ethyl acetate, the organic phases are washed with a 15% NaCl solution, the organic phases are dried over MgSO₄, the solvent is evaporated and the residue is chromatographed on silica gel, elution being carried out with an 85/15 (v/v) cyclohexane/ethyl acetate mixture, to isolate the expected product in the form of a resin.

¹H NMR, DMSO-d₆ 200 MHz : 8 (m, 2H), 7.5 (m, 3H), 7.04 (s, 0.75H), 6.85 (m, 1.25H), 4.0 (q, 2H), 3.6 (s, 3H), 3.66 (s, 4H), 3.58 (s, 3H), 3.5 (m, 1H), 1.9-1.6 (m, 8H), 1.34 (s, 9H), 1.28 (t, 3H).

5-Ethoxy-1-[4-(N',N'-diethylureido)-2-methoxybenzenesulphonyl]-3-spiro-[4-(2-tosyloxyethyloxy)-cyclohexane]indolin-2-one. Compound (II A.2)

0.25 g of tosyl chloride is added at 0°C to a solution of 0.18 ml of triethylamine and 0.25 g of 5-ethoxy-1-[4-(N',N'-diethylureido)-2-methoxybenzenesulphonyl]-3-spiro-[4-(2-hydroxyethyloxy)cyclohexane]-indolin-2-one (prepared in EP 0,636,608) in 3 ml of anhydrous tetrahydrofuran. The reaction mixture is stirred for 48 hours at 20°C, 10 ml of a saturated NaHCO₃ solution are added and then, successively, extraction is carried out with ethyl acetate, the organic phases are dried over MgSO₄, the solvent is evaporated and the residue is chromatographed on silica gel, eluent: 99/1 (v/v) and then 95/5 dichloromethane/methanol; M.p. = 80°C.

5-ethoxy-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl]-3-spiro-[4-(2-tosyloxyethyloxy)-cyclohexane]indolin-2-one. Compound (II A.3)

The expected product is isolated in a similar way as for the preparation of the compound (II A.2) starting from 5-ethoxy-1-[4-(2-hydroxyethyloxy)cyclohexane]indolin-2-one or by reacting 4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl chloride with the compound (III.4) in the conditions described for the preparation of the compound (II A.1) ; M.p. = 142°C.

PREPARATION VI Alcohols of formula (II'A)

5-Ethoxy-3-spiro-[4-(2-hydroxyethyloxy) cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl]-indolin-2-one. Compound (II' A.1)

a) 5-Ethoxy-3-spiro-[4-(2-nitrooxyethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl]indolin-2-one. Compound (II'A.1)

A mixture of 0.6 g of Compound (II A.1), 0.8 g of silver nitrate and 0.25 g of sodium iodide in 10 ml of acetonitrile is heated at reflux for 48 hours. The salts are separated

PREPARATION VII Indolin-2-one of formula (II.B)

5-Chloro-3-spiro-[4-(2-morpholinoethyloxy)-
cyclohexane]indolin-2-one (mixture of isomers).
Compound (II B.1)

5 A mixture of 0.57 g of Compound (III.3), 0.5 g of
morpholine and 0.27 g of NaI in 6 ml of dimethylformamide
is heated for 24 hours at 85°C. 10 ml of water are added
to the reaction mixture and 10 ml of a saturated NaHCO₃
solution are added and then, successively, extraction is
10 carried out twice with ethyl acetate, the organic phases
are dried over MgSO₄, the solvent is evaporated and the
residue is chromatographed on silica gel, elution being
carried out with dichloromethane and then with a 98/2
(v/v) dichloromethane/methanol mixture, to isolate 0.5 g
15 of the expected product in the form of an oil.

¹H NMR : 10.4 (s, 1H), 7.4 (s, 1H), 7.2 (d, 1H), 6.8
(d, 1H), 3.6 (m, 7H), 2.4 (m, 6H), 1.9-1.6 (m, 8H).

5-Ethoxy-3-spiro-[4-(2-N-*tert*-butyloxycarbonyl-N-
(benzyloxycarbonylmethyl)amino)ethyloxy)cyclohexane]-
20 indolin-2-one (mixture of isomers). Compound (II B.2)

1.5 g of tosylate (III.4) (mixture of isomers),
0.66 g of benzyl glycinate hydrochloride and 0.35 of
sodium carbonate in 80 ml of acetonitrile are heated at
60°C for 48 hours. The solvent is evaporated under
25 reduced pressure, the residue is taken up with 40 ml of
ethyl acetate, the organic phase is washed with water,
dried over Na₂SO₄ and the solvent is evaporated. The
residue is chromatographed on silica gel, elution being
carried out with a 99/1 (v/v) dichloromethane/methanol
30 mixture and a resin is isolated which is dissolved in 20
ml of dioxane. 0.13 g of MgO and 0.539 g of di-
*tert*butyldicarbonate dissolved in 10 ml of dioxane are
added at 5°C and the reaction mixture is stirred at 20°C
for 16 hours. The solvent is evaporated, the residue is
35 taken up with ethyl acetate, the organic phase is washed

0905400.04490
062710 00045000

successively with a buffer solution of pH = 2, a saturated sodium bicarbonate solution and water.

The drying is carried out on Na₂SO₄ and the solvent is evaporated. After purification by chromatography on silica gel, elution being carried out with a 5/5 (v/v) ethyl acetate/cyclohexane mixture, the expected product is obtained in the form of a resin.

¹H RMN : 10.12 (s, 0.3H); 10.03 (s, 0.7H); 7.30 (m, 5H); 6.88 (d, 1H); 6.70 (d, 2H); 5.14 (s, 0.7H); 5.12 (s, 0.3H); 4.05 (m, 2H); 3.95 (q, 2H); 3.3 to 3.6 (m, 5H); 1.4 to 2.1 (m, 8H); 1.2 to 1.4 (m, 12H).

5-Ethoxy-3-spiro-[4-(2-N-tert-butyloxycarbonyl-amino)ethyloxy)cyclohexane]indolin-2-one. Compound (II B.3)

a) 5-ethoxy-3-spiro-[4-(2-aminoethyloxy)cyclohexane]-indolin-2-one.

A mixture of 1.5 g of the compound (III.4) (obtained from the polar isomer (III'1), and 0.23 g of sodium azide in 15 ml of dimethylformamide is heated at 50°C for 16 hours. 30 ml of water are added, extraction is carried out twice with ethyl acetate. The organic phases are dried over Na₂SO₄, the solvent is evaporated partially under reduced pressure until a volume of about 20 ml. Said solution is hydrogenated at 60°C under a pressure of 10⁶ Pa in the presence of 0.6 g of Lindlar catalyst (Palladium over CaCO₃). The catalyst is filtered off and the solvent is evaporated under reduced pressure. The residue is chromatographed on a silica gel column, elution being carried out with a 90/10 (v/v) dichloromethane/methanol mixture. The hydrate hydrochloride of the expected product is isolated after recrystallization of the base in ethyl acetate followed by hydrochloration in ethyl acetate ; M.p. = 168°C.

b) 0.4 ml of 2N sodium hydroxide, 0.05g of magnesium oxide and 0.19 g of di-tert-butyldicarbonate dissolved in 7 ml of dioxane are added successively at about + 5°C to 0.27 g of the previous compound in 20 ml of dioxane.

After having stirred for 2 hours at 20°C, the solvent is evaporated, and then the residue is taken up with ethyl acetate, the organic phase is washed successively with a buffer solution of pH = 2, a saturated sodium bicarbonate solution and water. The drying is carried out on Na₂SO₄, the solvent is evaporated and the expected product is isolated in the form of a resin.

¹H RMN : 10.02 (s, 1H); 6.91 (s, 1H); 6.68 (s, 2H); 3.92 (q, 2H); 3.55-3.35 (m, 3H); 3.05 (m, 2H); 2.05-1.45 (m, 8H); 1.36 (s, 9H); 1.27 (t, 3H).

PREPARATION VIII Hydrazides of formula (VII)

N'-(4-Ethoxyphenyl)-4,4-ethylenedioxycyclohexane)-carbohydrazide. Compound (VII.1)

1.65 ml of isobutyl chloroformate are added, at -40°C, to a mixture of 2.63 g of sodium 4,4-ethylenedioxycyclohexaneate in 20 ml of tetrahydrofuran, followed by 1.8 ml of triethylamine. The reaction mixture is stirred for 2 hours at 0°C, 2.4 g of 4-ethoxyphenylhydrazine hydrochloride are then added at -20°C, the reaction mixture is stirred for 2 hours at 0°C, 100 ml of water are then added and extraction is carried out with ethyl acetate. The organic phases are washed successively with water, with a KHSO₄ solution (pH 2) and with a saturated potassium carbonate solution, dried over MgSO₄ and evaporated. The expected product is obtained after crystallization from diethyl ether; M.p. = 158°C.

N'-phenyl-4,4-ethylenedioxycyclohexanecarbohydrazide. Compound (VII.2)

Likewise, the compound (VII.2) is isolated from the phenylhydrazine. M.p. = 158°C.

PREPARATION IX Acetals of formula (IV')

5-Ethoxy-3-spiro-(4,4-ethylenedioxycyclohexane)-indolin-2-one. Compound IV'.1

2.15 ml of a 1.6M solution of butyllithium in hexane are added at -50°C to a suspension of 1 g of the hydrazide (VII.1) in 16 ml of tetrahydrofuran. The reaction mixture is stirred for 15 minutes and 16 ml of tetralin
5 are added. The tetrahydrofuran is distilled off and heating is carried out at 180°C for 45 minutes. 20 ml of ethyl acetate are then added at room temperature and then, successively, washing is carried out with water, the organic phase is dried over MgSO₄, the solvents are
10 distilled off under vacuum and the residue is chromatographed on silica gel, elution being carried out with a 7/3 (v/v) cyclohexane/ethyl acetate mixture. The expected product is isolated by crystallization from diethyl ether; M.p. = 183°C.

15 The same product is also obtained by reaction of 5-ethoxy-3-spiro-(4-oxocyclohexane)indolin-2-one (Compound V.1) with ethylene glycol in cyclohexane in the presence of 5 Å molecular sieve and a catalytic amount of para-toluenesulphonic acid.

20 5-Ethoxy-3-spiro-(4,4-propylenedioxycyclohexane)-indolin-2-one. Compound (IV'.2)

The preparation is carried out according to the same procedure described above for the preparation of Compound (IV'.1) from the corresponding hydrazide or by reaction of
25 5-ethoxy-3-spiro-(4-oxocyclohexane)indolin-2-one (Compound (V.1)) with 1,3-propanediol in cyclohexane in the presence of 5 Å molecular sieve and of a catalytic amount of para-toluenesulphonic acid; M.p. = 216°C.

30 3-Spiro-(4,4-ethylenedioxycyclohexane)indolin-2-one. Compound IV'3

The preparation is carried out according to the same procedure as above for the preparation of the compound (IV'.1) starting from the corresponding hydrazine (VII.2) ;

35 M.p. = 218°C.

elution being carried out with a 1/1 (v/v) cyclohexane/
ethyl acetate mixture; M.p. = 89°C.

PREPARATION XI Protected alcohols of formula (X)

5 5-Ethoxy-3-spiro-(4-methoxymethyloxycyclohexane)-
1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl]-
indolin-2-one. Compound (X.1)

0.283 g of potassium *tert*-butoxide is added to a
solution, cooled to -40°C, of 5-ethoxy-3-spiro-(4-methoxy-
10 methyloxycyclohexane)indolin-2-one (Compound of formula
(XI)), prepared according to EP 636,608, in 80 ml of
tetrahydrofuran. The temperature is allowed to rise to 0°C,
the mixture is then cooled to -40°C and 0.73 g of (2-
methoxy-4-N-*tert*-butylcarbamoyl)benzenesulphonyl chloride
15 in 7 ml of tetrahydrofuran is added. The reaction mixture
is stirred for 2 hours at room temperature and then,
successively, 20 ml of water are added, extraction is
carried out with ethyl acetate, drying is carried out
over MgSO₄, the solvent is evaporated and the oil
20 obtained is purified by chromatography on silica gel,
elution being carried out with an 8/2 (v/v)
cyclohexane/ethyl acetate mixture. The at least polar
isomer of the expected product is isolated; M.p. = 165°C,
followed by the polar isomer; M.p. = 156°C.

25

PREPARATION XII Alcohols of formula (IIc)

5-Ethoxy-3-spiro-(4-hydroxycyclohexane)-1-[4-(N-*tert*-
butylcarbamoyl)-2-methoxybenzenesulphonyl]indolin-2-one.
Compound (IIc.1)

30 A mixture of the polar isomer of Compound (X.1) in
1.2 ml of methanol and 0.24 ml of concentrated
hydrochloric acid (36%) is heated at 50°C for 1 hour.
8 ml of water are added to the reaction mixture and then,
successively, extraction is carried out with
35 dichloromethane, the organic phases are dried over MgSO₄
and the solvents are evaporated. The expected product is

obtained after purification by chromatography on silica gel, elution being carried out with dichloromethane; M.p. = 268°C (polar isomer).

In the same way, from the least polar isomer prepared according to (X.1), the least polar isomer of the expected product is isolated; M.p. = 130°C (hemihydrate). Compound (IIc.2)

PREPARATION XIII Reactants of formula (2)

2-Methoxy-4-N-*tert*-amylcarbamoylbenzenesulphonyl chloride. Reactant (2).1

a) N-*tert*-amyl-3-methoxy-4-nitrobenzamide

30 ml of *tert*-amylamine are added at 10°C to a solution of 27 g of 3-methoxy-4-nitrobenzoyl chloride (obtained from 25 g of the corresponding acid and thionyl chloride at reflux for 4 hours, followed by evaporation under vacuum) in 250 ml of dichloromethane. The reaction mixture is stirred for 30 minutes at 20°C, 100 ml of a 1N hydrochloric acid solution are then added, the organic phase is separated by settling, washed and dried over MgSO₄, the solvent is then evaporated and the residue is chromatographed on silica gel, elution being carried out with dichloromethane, to obtain 31 g of the expected product; M.p. = 65°C.

In the same way and from N-*tert*-butylamine, N-*tert*-butyl-3-methoxy-4-nitrobenzamide is prepared; M.p. = 118°C.

b) N-*tert*-amyl-3-methoxy-4-aminobenzamide

A mixture of 31 g of N-*tert*-amyl-3-methoxy-4-nitrobenzamide obtained in a), 20 g of 10% palladium-on-charcoal and 76 ml of cyclohexene in 310 ml of ethanol is heated at reflux for 3 hours. The mixture is filtered and the filtrate is evaporated to obtain 25 g of the expected product; M.p. = 108°C.

In the same way, from the compound N-*tert*-butyl-3-methoxy-4-nitrobenzamide, N-*tert*-butyl-3-methoxy-4-amino-benzamide is prepared; M.p. = 160°C.

c) 2-Methoxy-4-*tert*-amylcarbamoylbenzenesulphonyl chloride.

A solution of 7.9 g of sodium nitrite in 31 ml of water is added at 0°C to a solution of 25 g of *N-tert*-amyl-3-methoxy-4-aminobenzamide in 103 ml of acetic acid and 187 ml of 36% hydrochloric acid. The reaction mixture is stirred for 1 hour at 0°C and then this solution, stored at 0°C, is added to a suspension of 6.8 g of cupric chloride in 25 ml of water and 140 ml of acetic acid saturated at 0°C with approximately 69 g of sulphur dioxide. The reaction mixture is stirred at 0°C for 3 hours and then at 20°C for 16 hours and the mixture is poured onto 750 g of ice and subsequently stirred for 1 hour at 20°C. The precipitate is filtered off and then successively rinsed with water and dried under vacuum for 48 hours in order to obtain 19 g of the expected product; M.p. = 104°C.

4-*N-tert*-Butylcarbamoyl-2-methoxybenzenesulphonyl chloride. Reactant (2).2

In the same way, from *N-tert*-butyl-3-methoxy-4-aminobenzamide, the expected reactant is isolated; M.p. = 148°C.

3-Methoxy-4-benzyloxycarbonylbenzenesulphonyl chloride. Reactant (2).3

By using the same reaction as above, from the benzyl ester of 4-amino-3-methoxybenzoic acid (M.p. = 72°C, resulting from the reduction of the corresponding nitro derivative by tin in hydrochloric acid medium; M.p. = 88°C), the expected reactant is isolated; M.p. = 55°C.

N-tert-Butyl-4-bromomethyl-3-methoxybenzamide. Reactant (2).4


A mixture of 3 g of *N-tert*-butyl-4-methyl-3-methoxybenzamide, 2.4 g of *N*-bromosuccinimide and 0.16 g of benzoyl peroxide in 40 ml of carbon tetrachloride is stirred at 30°C while irradiating in the visible spectrum for 48 hours. The solvent is evaporated and then,

successively, 25 ml of water are added, extraction is carried out with diethyl ether, drying is carried out over MgSO_4 , the solvent is evaporated and the residue is chromatographed on silica gel, elution being carried out with an 8/2 (v/v) cyclohexane/ethyl acetate mixture. The expected reactant is isolated after crystallization from isopropyl ether; M.p. = 114°C .

EXAMPLE 1

5-Ethoxy-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxy-benzenesulphonyl]-3-spiro-[4-(2-morpholinoethyloxy)cyclohexane]indolin-2-one.

(I): $\text{R}_1 = 5\text{-OC}_2\text{H}_5$; $\text{R}_2 = \text{H}$; $\text{R}_3 = 2\text{-OCH}_3$; $\text{W} = \text{SO}_2$;



the least polar isomer.

A mixture of 0.6 g of the chlorinated derivative (II A.1) obtained according to PREPARATION V, 0.26 g of morpholine and 0.15 g of sodium iodide in 6 ml of dimethylformamide is heated at 60°C under an inert atmosphere for 40 hours. The solvent is evaporated under vacuum and then, successively, the residue is taken up in 20 ml of a 5% aqueous NaHCO_3 solution, extraction is carried out with ethyl acetate, the organic phases are washed with a 10% NaCl solution and dried over MgSO_4 , the solvent is evaporated and a resin is isolated which is chromatographed on silica gel, elution being carried out with a 98/2 (v/v) dichloromethane/methanol mixture.


The least polar isomer of the expected product is isolated ($\text{R}_f = 0.5$; silica TLC; 95/5 (v/v) dichloromethane/methanol). The fumarate is prepared in acetone and is crystallized from diethyl ether; M.p. = 153°C (EXAMPLE 1).

^1H NMR, DMSO-d_6 200 MHz : 8.0 (m, 2H), 7.5 (m, 2H), 7.4 (s, 1H), 6.88 (d, 1H), 6.82 (s, 1H), 6.6 (s, 2H, fumaric acid), 4.0 (q, 2H), 3.6 (s, 3H), 3.55 (m, 7H), 2.45 (m, 6H), 2-1.4 (m, 8H), 1.34 (s, 9H), 1.3 (t, 3H).

EXAMPLE 2

5-Ethoxy-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxy-benzenesulphonyl]-3-spiro-[4-(2-morpholinoethyloxy)cyclohexane]indolin-2-one.

(I): $R_1 = 5\text{-OC}_2\text{H}_5$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;



the most polar isomer.

The most polar isomer of the product prepared above according to EXAMPLE 1 is isolated under the above conditions; $R_f = 0.43$; M.p. = 212°C - 216°C .

^1H NMR, DMSO- d_6 200 MHz : 8.0 (m, 2H), 7.5 (m, 2H), 7.4 (s, 1H), 7.03 (s, 1H); 6.84 (d, 1H), 6.6 (s, 2H, fumaric acid), 4.0 (q, 2H), 3.6 (s, 3H), 3.5 (m, 6H), 3.40 (m, 1H), 2.45 (m, 6H), 1.9-1.6 (m, 8H), 1.34 (s, 9H), 1.3 (t, 3H).


The fumarate is prepared in acetone and is crystallized from diethyl ether; M.p. = 172°C (EXAMPLE 2).

Monohydrated dihydrogenophosphate is prepared by reacting the monohydrated phosphoric acid with the base in ethanol ; M.p. = 170°C . The nitrate is prepared by reacting aqueous nitric acid with the base in ethanol ; M.p. = 155°C .

EXAMPLE 3

5-Ethoxy-1-[4-(N',N'-diethylureido)-2-methoxy-benzenesulphonyl]-3-spiro-[4-(2-dimethylaminoethyloxy)-cyclohexane]indolin-2-one.

(I): $R_1 = 5\text{-OC}_2\text{H}_5$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;



A mixture of 0.23 g of the tosylated derivative (II A.2) obtained above according to PREPARATION V in 3.3 ml of acetonitrile and 0.23 ml of a 40% aqueous

10

15

(I): $R_1 = 5\text{-OC}_2\text{H}_5$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;
 $R_4 = 4\text{-CONHC}(\text{CH}_3)_3$; T-Z = $-\text{CH}_2\text{CH}_2\text{NH}_2$

20

25

35


(v/v) dichloromethane/methanol mixture. The expected product is isolated in the base form and is salified with fumaric acid in acetone and crystallized from isopropyl ether to obtain the expected product ; M.p. = 138°C (monohydrate).

In the same way, from the compound (II A.3) and by the same steps, the polar isomer of the expected product is isolated, the hemihydrated hydrochloride of which melts at 174°C.

EXAMPLE 5

5-Chloro-3-spiro-[4-(2-morpholinoethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl]indolin-2-one.

(I): $R_1 = 5\text{-Cl}$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;




0.073 g of potassium *tert*-butoxide is added to a solution, cooled to -30°C, of 0.21 g of Compound (II B.1) obtained above according to PREPARATION VII in 24 ml of tetrahydrofuran. The temperature is allowed to rise to 0°C, the mixture is then cooled to -40°C and 0.19 g of [2-methoxy-4-(N-*tert*-butylcarbamoyl)]benzenesulphonyl chloride in 2 ml of tetrahydrofuran is added. The reaction mixture is then stirred for 2 hours at -10°C, 15 ml of water are added and then, successively, extraction is carried out with ethyl acetate, drying is carried out over MgSO_4 , the solvent is evaporated and the residue is purified by chromatography on silica gel, elution being carried out with dichloromethane and then with a 96/4 dichloromethane/methanol mixture. The polar isomer of the expected product is isolated and is salified with fumaric acid in acetone. The fumarate is crystallized from diisopropyl ether; M.p. = 107°C (tri-hemihydrate).

EXAMPLE 6

5-Ethoxy-3-spiro-[4-(2-carboxyethyloxy)cyclohexane]-
1-[4-(N-*tert*-amylcarbamoyl)-2-methoxybenzenesulphonyl]-
indolin-2-one.

(I): $R_1 = 5-OC_2H_5$; $R_2 = H$; $R_3 = 2-OCH_3$; $W = SO_2$;



1 g of chromium oxide is added at 0°C to a mixture
of 1.5 g of Compound (II' A.2) obtained according to
PREPARATION VI in 9 ml of acetic acid and 10 ml of water.
The reaction mixture is stirred for two hours at 20°C,
80 ml of water are then added and, successively,
extraction is carried out with ethyl acetate, the organic
phases are dried over $MgSO_4$, the solvent is distilled and
the expected product is isolated after chromatography on
silica gel, elution being carried out with a 99/1 (v/v)
dichloromethane/methanol mixture; M.p. = 108°C
(hemihydrate).

EXAMPLE 7

5-Ethoxy-3-spiro-(4-ethoxycarbonylmethyloxycyclo-
hexane)-1-[(4-N-*tert*-butylcarbamoyl-2-methoxy)benzene-
sulphonyl]indolin-2-one.

(I): $R_1 = 5-OC_2H_5$; $R_2 = H$; $R_3 = 2-OCH_3$; $W = SO_2$;

$R_4 = 4-CONHC(CH_3)_3$; $T-Z = -CH_2-COO-C_2H_5$

0.47 g of 2,6-di-*tert*-butylpyridine, 0.54 g of
silver trifluoromethanesulphonate and then 0.27 ml of
ethyl iodoacetate are added at 0°C to a solution of
0.75 g of 5-ethoxy-3-spiro-(4-hydroxycyclohexane)-1-[4-(N-
tert-butylcarbamoyl)-2-methoxybenzenesulphonyl]indolin-2-one
(II.C1) in 30 ml of dichloromethane. The reaction mixture
is stirred for 48 hours at 20°C and then, successively,

the reaction mixture is filtered, the solvent is evaporated and the expected product is isolated after chromatography on silica gel, elution being carried out with cyclohexane and then with a 20/80 (v/v) cyclohexane/dichloromethane mixture, and recrystallization from isopropanol; M.p. = 165°C.

EXAMPLE 8

5-Ethoxy-3-spiro-(4-carboxymethyloxycyclohexane)-1-(4-N-*tert*-butylcarbamoyl-2-methoxybenzenesulphonyl)-indolin-2-one.


(I): $R_1 = 5\text{-OC}_2\text{H}_5$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;

$R_4 = 4\text{-CONHC(CH}_3)_3$; $\text{T-Z} = \text{-CH}_2\text{COOH}$

0.34 g of the product obtained in EXAMPLE 7 and 0.01 g of para-toluenesulphonic acid in 3 ml of benzyl alcohol are heated at 65° for 16 hours. The solvent is evaporated and then, successively, 1 ml of water and 1 ml of a saturated NaHCO_3 solution are added, extraction is carried out with ethyl acetate, the solvent is evaporated and then 5 ml of isopropanol, 0.25 g of 10% palladium-on-charcoal and 0.25 ml of cyclohexene are added. The reaction mixture is heated at 80°C for 3 hours and then, successively, the reaction mixture is filtered, the catalyst is rinsed with methylene chloride, the solvents are evaporated and the expected product is isolated and purified by chromatography on silica gel, elution being carried out with a 98/2 (v/v) dichloromethane/methanol mixture. The fraction of the expected product is recrystallized from an 8/2 (v/v) isopropyl ether/ethyl acetate mixture; M.p. = 175°C (hemihydrate).








EXAMPLES 9 to 23 described in TABLE 1 below are prepared according to EXAMPLES 1 to 8 above.

TABLE 1








Example Number	R ₁	W	R ₄	T	Z	Salt, Solvates (1)	M.p. ; °C
9	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂ -		1 H ₂ O	170
10	Cl	SO ₂	-OCH ₃	-(CH ₂) ₂ -		fumarate 1.5 H ₂ O	88
11	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂ -		fumarate 2 H ₂ O	160
12	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₃ -		- (3)	80
13	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₃ -		fumarate 2 H ₂ O	170

TABLE 1 (continuation 1)

Example Number	R ₁	W	R ₄	T	Z	Salt, Solvates (1)	M.p. ; °C
14	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂ -	-N(CH ₃) ₂	fumarate 1 H ₂ O	150
15	-OC ₂ H ₅	CH ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂ -		fumarate 1 H ₂ O	110
16	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂ -		fumarate 1 H ₂ O	165
17	-OC ₂ H ₅	SO ₂		-(CH ₂) ₂ -		-	65
18	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂ -		fumarate 1.5 H ₂ O	190
19	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂ -		fumarate 4 H ₂ O	208
20	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂ -		fumarate 1 H ₂ O (2)	104



864740 00675050

TABLE 1 (continuation 2)

Example Number	R ₁	W	R ₄	T	Z	Salt, Solvates (1)	M.p. ; °C
21	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂		fumarate 1.5 H ₂ O	100
22	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂		dioxalate 1 H ₂ O	224
23	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂	-N(CH ₂ CH ₂ OCH ₃) ₂	fumarate 1 H ₂ O	98
24	H	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₃	COOH	-	183
25	Cl	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₃	COOH	-	163
26	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂		H ₂ O	114
27	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂		HCl H ₂ O (4)	150
28	-OC ₂ H ₅	SO ₂	-COOCH ₂ C ₆ H ₅	-(CH ₂) ₂		H ₂ O	80

2025 RELEASE UNDER E.O. 14176

Table 1 (continuation 3)

Example Number	R ₁	W	R ₄	T	Z	Salt, Solvates (1)	M.p. ; °C
29	-OC ₂ H ₅	SO ₂	-COOCH ₂ C ₆ H ₅	-(CH ₂) ₂		- (4)	55
30	-OCH ₂ C ₆ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂		-	62
31	-OC ₂ H ₅	SO ₂	-CONHC(CH ₃) ₃	-(CH ₂) ₂	N(CH ₂ C ₆ H ₅) (CH ₂) ₂ O (CH ₂) ₂ OH	(5)	69

(1): The most polar isomers, except when otherwise indicated

(2): Mixture of isomers

(3): The least polar isomer

(4): The 4-hydroxypiperidine ethers are obtained by alkylation of the N-*tert*-butyloxycarbonyl-4-hydroxypiperidine and of the corresponding halide in the presence of sodium hydride followed by an acid hydrolysis of the *tert*-butyloxycarbonyl group.

(5): The 2-(2-(N-benzylamino)ethoxy)ethanol was prepared by reducing amination by sodium borohydride of the imine issued from 2-(2-aminoethoxy)ethanol and benzaldehyde, in methanol and at 0°C.

EXAMPLE 32

5-Ethoxy-3-spiro-[4-(2-(2-hydroxyethylamino)-ethyloxy)cyclohexane]-1-[4-(4-N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one (polar isomer).

5 (I): $R_1 = 5\text{-OC}_2\text{H}_5$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;
 $R_4 = 4\text{-CONHC(CH}_3)_3$; $\text{T-Z} = \text{CH}_2\text{CH}_2\text{NHCH}_2\text{CH}_2\text{OH}$;

a) 0.33 g of benzyloxyacetaldehyde and then 0.46 g of sodium triacetoxyborohydride are added to a solution of 0.9 g of the amine hydrochloride of EXAMPLE 4 (polar isomer) in 8 ml of tetrahydrofuran, cooled to 5°C. The
10 reaction mixture is stirred at 20°C for 3 hours, 10 ml of 1N HCl are added, extraction is carried out with ethyl acetate, the organic phase is washed with a saturated NaCl solution, dried over MgSO_4 and the solvent is
15 evaporated under reduced pressure. The residue is chromatographed on a silica gel column, elution being carried out with a 98/2 (v/v) dichloromethane/methanol mixture.

b) 0.4 ml of 1,4 cyclohexadiene, 0.3 g of (10 %) Palladium/C are added to the benzyl ether previously
20 obtained, dissolved in 5 ml of glacial acetic acid and are heated at 60°C under nitrogen bubbling for 16 hours according to the method described in J. Org. Chem. 43, 21 (1978).

The catalyst is filtered off, 10 ml of water are
25 added to the reaction mixture, which is neutralized with a saturated NaHCO_3 solution; the extraction is carried out with ethyl acetate, washing is carried out with water, drying is effected over MgSO_4 and the solvent is evaporated under reduced pressure. The residue is
30 chromatographed on a silica gel column, elution being carried out with a 98/2 (v/v) dichloromethane/methanol mixture. The expected product is isolated in the form of hydrate hydrochloride by preparing the hydrochloride with a hydrochloric isopropanol solution and cristallization
35 from diethyl ether, M.p. = 130°C.

005400.0478
06240°0054068

EXAMPLE 33

5-Ethoxy-3-spiro-[4-(2-(2-(2-hydroxyethyloxy)-ethylamino)ethyloxy)cyclohexane]-1-[4-(4-N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one.


5 The expected compound in the form of the trihemihydrated hydrochloride is isolated by debenzoylation of the compound of EXAMPLE 31 according to the procedure described in EXAMPLE 32b) in ethanol and by preparing the hydrochloride in ethyl ether ; M.p. = 159°C.

10

EXAMPLE 34

5-Ethoxy-3-spiro-[4-(2-(4-benzyloxypiperidino)-ethyloxy)cyclohexane]-1-[4-carboxy-2-methoxybenzenesulfonyl]indolin-2-one.

15 (I): $R_1 = 5\text{-OC}_2\text{H}_5$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;



(prepared by selective debenzoylation according to Tetrah. Letters, 1986, 3753).


0.62 ml of *tert*-butyldimethylsilane and 0.06 ml of triethylamine are added to 0.03 g of Palladium acetate solution in 4 ml of dichloromethane and the reaction medium is stirred for 15 minutes at 20°C. A solution of 1 g of the compound described in EXAMPLE 29 in 2.6 ml of dichloromethane is added slowly and stirring is carried out for 4 hours at 20°C. 1 ml of acetic acid is added, followed by filtration, rinsing with dichloromethane and the filtrate is washed with an aqueous ammonium chloride solution and then with water. The expected product is isolated after evaporation of the solvent, cristallization from pentane and drying at 50°C under vacuum for 5 hours ; M.p. = 120°C.

434743 00675000

EXAMPLE 35

5-Ethoxy-3-spiro-[4-(2-(4-benzyloxypiperidino)-ethyloxy)cyclohexane]-1-[4-(N-(1-hydroxymethyl)cyclopentylcarbamoyl-2-methoxybenzenesulfonyl]indolin-2-one.

(I): $R_1 = 5-OC_2H_5$; $R_2 = H$; $R_3 = 2-OCH_3$; $W = SO_2$;




1.27 g of oxalyl chloride are added to a suspension of 0.7 g of the compound prepared in EXAMPLE 34 in 7 ml of toluene and 2.5 ml of dichloromethane and the reaction mixture is stirred for 6 hours at 20°C. The solvents are evaporated, the residue is dried for 2 hours at 20°C under vacuum and is dissolved in 20 ml of toluene then this solution is added to a solution cooled to about -40°C of 1.16 g of 1-amino-1-cyclopentane-methanol in 30 ml of toluene. The reaction mixture is stirred for 2 hours at 20°C, 30 ml of water and 100 ml of ethyl acetate are added. The organic phase is dried over Na_2SO_4 and evaporated under reduced pressure. The expected product is isolated after chromatography on silica gel, elution being carried out with a 95/5 (v/v) dichloromethane/ methanol mixture ; M.p. = 103°C.

EXAMPLE 36

5-Ethoxy-3-spiro-[4-(2-(4-hydroxypiperidino)-ethyloxy)cyclohexane]-1-[4-(N-(1-hydroxymethyl)cyclopentylcarbamoyl-2-methoxybenzenesulfonyl]indolin-2-one.

(I): $R_1 = 5-OC_2H_5$; $R_2 = H$; $R_3 = 2-OCH_3$; $W = SO_2$;



The expected product is isolated in the form of a hydrated base, according to the procedure described in EXAMPLE 32 b) starting from EXAMPLE 35, after chromatography on a silica gel column, elution being

carried out with a 92/8 (v/v) dichloromethane/methanol mixture ; M.p. = 109°C.

EXAMPLE 37

5 5-Ethoxy-3-spiro-[4-(2-(benzyloxycarbonylméthyl-amino)ethyloxy)cyclohexane]-1-[4-(4-N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one.

(I): $R_1 = 5-OC_2H_5$; $R_2 = H$; $R_3 = 2-OCH_3$; $W = SO_2$;

$R_4 = 4-CONHC(CH_3)_3$; T-Z = $-CH_2CH_2NHCH_2COOCH_2C_6H_5$

10 A residue is isolated according to the procedure described in EXAMPLE 5 starting from the compound (II B.2) and the 2-methoxy-4(N-*tert*-butylcarbamoyl)benzenesulphonyl chloride, and stirred for 2 hours at 20°C in 3 ml of a ethyl acetate solution which is saturated with gaseous
15 hydrochloric acid. The expected product is obtained after alkalization and chromatography on silica gel, elution being carried out with an 8/2 (v/v) cyclohexane/ethyl acetate mixture ; the monohydrated hydrochloride melts at 160°C.

20

EXAMPLE 38

5-Ethoxy-3-spiro-[4-(2-(carboxymethylamino)ethyloxy)-cyclohexane]-1-[4-(4-N-*tert*-butylcarbamoyl)-2-methoxy-benzenesulfonyl]indolin-2-one.

25 (I): $R_1 = 5-OC_2H_5$; $R_2 = H$; $R_3 = 2-OCH_3$; $W = SO_2$;

$R_4 = 4-CONHC(CH_3)_3$; T-Z = $-CH_2CH_2NHCH_2COOH$


0.06 g of the compound of EXAMPLE 37, 6 g of cyclohexene, 0.05 g of 10 % Palladium/charcoal in 10 ml of ethanol are heated to reflux for 1 hour 30, the
30 catalyst is filtered off and the solvent is evaporated under reduced pressure. The expected product is isolated in a dihydrated form after chromatography on silica gel, elution being carried out with a 90/10 (v/v) dichloromethane/methanol mixture ; M.p. = 199°C.

35

000000 0149 000000

EXAMPLE 39


5-Hydroxy-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]-3-spiro-[4-(2-morpholinoethyloxy)cyclohexane]indolin-2-one. (mixture of isomers)



The expected product is isolated in a hydrated form according to the procedure described in EXAMPLE 38 starting from the compound of EXAMPLE 30 ; M.p. = 125°C.

EXAMPLE 40

5-Ethoxy-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]-3-spiro-[4-(2-N-oxide morpholinoethyloxy)-cyclohexane]indolin-2-one.




0.8 ml of 30 % hydrogen peroxide is added to 0.5 g of the compound described in EXAMPLE 2 dissolved in 10 ml of methanol and the reaction mixture is heated to 45°C for 16 hours. The solvent is evaporated under reduced pressure and the residue is chromatographed on silica gel, elution being carried out with an 85/15 (v/v) dichloromethane/methanol mixture. The expected product is isolated in a hemihydrated form after recrystallization from a 40/60 (v/v) cyclohexane/ethyl acetate mixture ; M.p. = 189°C.

EXAMPLE 41

Methylsulfate of 5-Ethoxy-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]-3-spiro-[4-(2-N-methylmorpholiniummethyloxy)cyclohexane]indolin-2-one.

(I): $R_1 = 5\text{-OC}_2\text{H}_5$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;



0.05 ml of dimethylsulphate is added to 0.25 g of the compound described in EXAMPLE 2 dissolved in 2.5 ml of acetonitrile and the reaction mixture is heated at 60°C for 24 hours. The solvent is evaporated and the expected product is isolated in a hemihydrated form after cristallization from diethyl ether and drying at 40°C under vacuum for 5 hours ; M.p. = 190°C.

EXAMPLE 42

5-Ethoxy-3-spiro-[4-(2-(2-(N-*tert*-butoxycarbonyl-glycyl)amino)ethyloxy)cyclohexane]-1-[4-(4-N-*tert*-butyl-carbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one.

(I): $R_1 = 5\text{-OC}_2\text{H}_5$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;

$R_4 = 4\text{-CONHC(CH}_3)_3$;

$\text{T-Z} = -\text{CH}_2\text{CH}_2\text{-NHCOCH}_2\text{NHCOOC(CH}_3)_3$

0.28 g of benzotriazol-1-yl-oxy-tris(dimethylamino)-phosphonium hexafluorophosphate and 0.24 ml of triethylamine and then 0.35 g of the hydrochloride of the compound of EXAMPLE 4 (polar isomer) are added at 5°C to a solution of 0.11 g of N- α -*tert*-butyloxycarbonylglycine in 2 ml of acetonitrile and stirring is carried out at about 20°C for 4 hours.

The solvent is evaporated under reduced pressure, the residue is taken up with ethyl acetate, washed successively with a $\text{KHSO}_4/\text{K}_2\text{SO}_4$ buffer solution of pH = 2, with water, with a saturated NaHCO_3 solution and then with water. The organic phase is dried over MgSO_4 and the solvent is evaporated under reduced pressure and the residue is chromatographed on a silica gel column, elution being carried out with a 99/1 (v/v) dichloromethane/methanol mixture. The expected product is isolated ; M.p. = 158°C.

EXAMPLE 43

5-Chloro-3-spiro-[4-(N-(3-dimethylaminopropyl)-
carbamoylmethoxy)cyclohexane]-1-[4-(4-N-*tert*-butyl-
carbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one.

5 (I): $R_1 = 5\text{-Cl}$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;
 $R_4 = 4\text{-CONHC(CH}_3)_3$; $\text{T-Z} = \text{-CH}_2\text{CONH(CH}_2)_3\text{N(CH}_3)_2$


The expected product is isolated in a monohydrated
hydrochloride form according to the procedure described
in EXAMPLE 42 and starting from the carboxylic acid of
10 EXAMPLE 25 and 3-dimethylaminopropanamine; M.p. = 135°C.

The compounds 44 to 50 collated in Table 2 below are
prepared according to the procedures of EXAMPLES 42 and
43 by reacting amines or acids appropriately selected.

15

834740 0054863

TABLE 2



Example Number	R ₁	T	Z	Salt, Solvate (1)	M.p. ; °C
44	5-OC ₂ H ₅	-(CH ₂) ₂ -	-NHCO(CH ₂) ₃ N(CH ₃) ₂	HCl	151
45	5-OC ₂ H ₅	-(CH ₂) ₂ -	-NHCO(CH ₂) ₃ COOCH ₃	-	138
46	5-OC ₂ H ₅	-(CH ₂) ₂ -	-NHCOCH ₂ N(CH ₃) ₂	HCl H ₂ O	144
47	5-OC ₂ H ₅	-(CH ₂) ₂ -	-NHCO(CH ₂) ₂ OCH ₃	1H ₂ O	108
48	5-OC ₂ H ₅	-(CH ₂) ₂ -	-NHCO(CH ₂) ₂ CH (NHCOOC(CH ₃) ₃)COOC(CH ₃) ₃	(4) H ₂ O	133
49	5-OC ₂ H ₅	-(CH ₂) ₂ -	-NHCOCH(NHCOOCH ₂ C ₆ H ₅) (CH ₂) ₂ COOCH ₂ C ₆ H ₅	(5)	108
50	H	CH ₂	-CONH(CH ₂) ₂ OH	0.5 H ₂ O	183

- (4) starting from *tert*-butyl N- α -*tert*-butoxyglutamate in natural configuration.
- (5) from the γ -benzylic ester of N- α -benzyloxycarbonyl-glutamic acid in natural configuration.

5

EXAMPLE 51

5-Ethoxy-3-spiro-[4-(2-glycylaminoethoxy)-cyclohexane]-1-[4-(4-N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one.

- 10 (I): $R_1 = 5\text{-OC}_2\text{H}_5$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;
 $R_4 = 4\text{-CONHC(CH}_3)_3$; T-Z = $-\text{CH}_2\text{CH}_2\text{NHCOCH}_2\text{NH}_2$

- 3 ml of a saturated solution of gaseous hydrochloric acid in ethyl acetate are added at 5°C to a suspension of 0.3 g of the compound of EXAMPLE 42 in 3 ml of ethyl acetate and the reaction mixture is stirred for 2 hours at room temperature. The solvent is evaporated, cristallization is carried out from diethyl ether, drying is carried out under vacuum to obtain the expected product in the form of a dihydrated hydrochloride ;
- 15
- 20 M.p. = 169°C.

EXAMPLE 52

- 5-Ethoxy-3-spiro-[4-(2-(4-carboxybutyramido)ethyloxy)cyclohexane]-1-[4-(4-N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one.
- 25

- (I): $R_1 = 5\text{-OC}_2\text{H}_5$; $R_2 = \text{H}$; $R_3 = 2\text{-OCH}_3$; $W = \text{SO}_2$;
 $R_4 = 4\text{-CONHC(CH}_3)_3$; T-Z = $-\text{CH}_2\text{CH}_2\text{NHCO(CH}_2)_3\text{COOH}$

- The expected product is isolated from the compound of EXAMPLE 45 and according to the procedure of EXAMPLE 8 by transesterification with benzylic alcohol followed by hydrogenolysis. M.p. = 117°C.
- 30

EXAMPLE 53

- 5-Ethoxy-3-spiro-[4-(2-L- γ -glutamylamino)ethyloxy)-cyclohexane]-1-[4-(4-N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one.
- 35

$$\text{T-Z} = -\text{CH}_2\text{CH}_2\text{NHCOCH}_2\text{CH}_2\text{CH}(\text{NH}_2)\text{COOH}$$

EXAMPLE 54


10 5-Ethoxy-3-spiro-[4-(2-L-pyroglutamylamino)ethyloxy)-
cyclohexane]-1-[4-(4-N-*tert*-butylcarbamoyl)-2-
methoxybenzenesulfonyl]indolin-2-one.

$$R_4 = 4\text{-CONHC(CH}_3)_3 ; \text{ T-Z} = \text{-CH}_2\text{CH}_2\text{NHCO} \begin{array}{c} \diagup \quad \diagdown \\ \text{C} \quad \text{C} \\ \diagdown \quad \diagup \\ \text{N} \\ | \\ \text{H} \end{array} \text{C=O}$$

15 A mixture of 0.245 g of the compound of EXAMPLE 49,
0.5 ml of cyclohexadiene and 0.25 g of 10 %
Palladium/charcoal in 2 ml of ethyl acetate is heated at
80°C. The catalyst is separated by filtration,
evaporation is carried out under reduced pressure and the
20 residue is taken up with ethyl acetate and washed with a
saturated sodium bicarbonate. The solvent is evaporated
under reduced pressure and the residue is chromatographed
on a silica gel column, elution being carried out with a
98/2 (v/v) dichloromethane/methanol mixture. The
25 resulting residue is taken up with diethyl ether; M.p. =
171°C.

CLAIMS

1. Compound of formula



in which:

- 5 - R₁ and R₂ each independently represent a hydrogen; a hydroxyl; a halogen; a (C₁-C₇)alkyl; a (C₁-C₇)polyfluoroalkyl; a (C₁-C₇)alkoxy; a (C₁-C₇)-alkylthio; a (C₁-C₇)polyfluoroalkoxy; a (C₃-C₇)cycloalkyloxy; a (C₃-C₇)cycloalkylthio; a cycloalkylmethoxy or a cycloalkyl-methylthio in which the cycloalkyl is C₃-C₇; a phenoxy; a benzyloxy; a nitro; or a cyano;
- 10 - R₃ and R₄, each independently of one another, substitute the phenyl group one or a number of times and represent a hydrogen; a halogen; a (C₁-C₇)alkyl; a (C₂-C₇)alkenyl; a (C₁-C₇)polyhaloalkyl; a phenyl or a benzyl; a cyano; a nitro; an -NR₅R₆ group; a hydroxyamino; a hydroxyl; an OR₇ group; an SR₇ group; a -COOR₈ group, a -CONR₉R₁₀ group; or a -CSNR₉R₁₀ group, at least
- 15 one of the R₃ and R₄ radicals being other than hydrogen;
- R₅ and R₆ each independently represent a hydrogen; a (C₁-C₇)alkyl; a (C₂-C₇)alkenyl; a phenyl; a benzyl; a (C₁-C₇)alkylcarbonyl; a (C₁-C₇)alkylthiocarbonyl; a (C₃-C₇)cycloalkylcarbonyl; a (C₃-C₇)cycloalkylthiocarbonyl; a benzoyl; a thienylcarbonyl; a furylcarbonyl; a (C₁-C₇)alkyloxycarbonyl; a
- 20 phenoxycarbonyl; a benzyloxy-carbonyl; a carbamoyl or a thiocarbamoyl which is unsubstituted or substituted by R₉ and R₁₀ or alternatively R₅ and R₆ form, with the nitrogen atom to which they are bonded, a heterocyclic group chosen from the pyrrolidine, pyrroline, pyrrole, indoline, indole and piperidine groups;


- R₇ represents a (C₁-C₇)alkyl; a (C₂-C₇)alkenyl; a phenyl; a benzyl; a (C₃-C₇)cycloalkyl; a (C₁-C₇)poly-fluoroalkyl; a formyl; a (C₁-C₇)alkylcarbonyl; a benzoyl; or a benzylcarbonyl;
- R₈ represents a hydrogen; a (C₁-C₇)alkyl; a phenyl; or a benzyl;
- 5 - R₉ and R₁₀ each independently represent hydrogen; a (C₁-C₇)alkyl; a (C₁-C₇)polyfluoroalkyl; a (C₂-C₇)alkenyl; a (C₃-C₇)cycloalkyl optionally substituted by a hydroxy (C₁-C₄)alkyl; a pyridyl; a phenyl; a thienyl; a furyl; or alternatively R₉ and R₁₀ form, with the nitrogen atom to which they are bonded, a heterocyclic group chosen from the pyrrolidine, piperidine and piperazine groups, which is unsubstituted or
- 10 substituted by (C₁-C₄)alkyls; and the (C₄-C₇)azacycloalkyl groups;
- W represents a -CH₂- or -SO₂- group;
- Cy forms, with the carbon to which it is bonded, a non-aromatic, saturated or unsaturated C₃-C₁₂ hydrocarbon ring which is optionally condensed or substituted by one or a number of (C₁-C₇)alkyl groups, it being possible for the
- 15 said groups to substitute the same carbon atom one or a number of times, or by a C₃-C₆ spirocycloalkyl;
- T represents a (C₁-C₄)alkylene which is optionally interrupted by a (C₃-C₆)cycloalkylene, the said alkylenes optionally being substituted one or a number of times on the same carbon atom by a (C₁-C₃)alkyl; or alternatively T represents a
- 20 direct bond;
- Z represents an -NR₁₁R₁₂ group; -⁺NR₁₁R₁₂(C₁-C₄)-alkyl (A⁻), (A⁻) being an anion; -N(O)R₁₁R₁₂; a -COOR₁₁ group; an -NR₁₁COR₁₂ group; a benzyloxycarbonylamino; a -CONR₁₁R₁₂ group; it being understood that when T represents a methylene or a direct bond, Z cannot be -NR₁₁R₁₂; -⁺NR₁₁R₁₂(C₁-C₄)alkyl; -N(O)R₁₁R₁₂; -NR₁₁COR₁₂; a benzyloxycarbonylamino;
- 25 - R₁₁ and R₁₂ each independently represent hydrogen; a (C₁-C₇)alkyl; a (C₁-C₄)alkoxy; a (C₃-C₇)cycloalkyl; a phenyl; a (C₁-C₃)alkylenecycloalkyl, in which the cycloalkyl is C₃-C₇, or a (C₁-C₃)alkylenephenyl, it being possible for the said groups optionally to be mono- or polysubstituted by R₁₃ ;
- 30 or alternatively R₁₁ and R₁₂ optionally form, with the nitrogen atom to which they are bonded, a heterocycle chosen from azetidine, pyrrolidine, piperidine, piperazine, piperazinone, morpholine, morpholinone, thiomorpholine and hexahydroazepine heterocycles, which heterocycle is optionally mono- or polysubstituted by R₁₃; or a

thiomorpholine 1,1-dioxide or a thiomorpholine 1-oxide; or alternatively R₁₂ represents a pyrrolidone or a piperidone ;

- R₁₃ represents a hydroxyl group; a (C₁-C₄)alkyl; a (C₁-C₄)alkoxy; a mercapto; a (C₁-C₄)alkylthio; a (C₁-C₄)-alkylsulphinyl; a (C₁-C₄)alkylsulphonyl; a benzyloxy; a hydroxyalkyloxy; an -NR₁₄R₁₅ group in which R₁₄ and R₁₅ each independently represent hydrogen or a (C₁-C₄)alkyl or a (C₁-C₄)alkyloxycarbonyl or a benzyloxycarbonyl; a carboxyl; a (C₁-C₄)alkyloxycarbonyl, a phenoxycarbonyl, a benzyloxycarbonyl ; a carbamoyl; an amidino; a guanidino; an imidazolyl; a thienyl; a pyridyl; an indolyl; or a tetrahydroisoquinolyl;


- the phenyl group, which is constituent of the R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁ and R₁₂ substituents, being unsubstituted, mono- or disubstituted by a (C₁-C₇)alkyl, a (C₁-C₇)alkoxy, a tri-fluoromethyl, a halogen or trisubstituted by a (C₁-C₇)-alkyl, a (C₁-C₇)alkoxy or a halogen ; and their salts.

2. Compound according to claim 1 of formula:




in which R₁, R₃, R₄, W, T and Z are as defined for (I) in claim 1 or one of its salts, solvates or hydrates.

3. Compound according to claim 1 of formula:




5 in which R_1 , R_3 , R_4 , T and Z are as defined for (I) in claim 1 or one of its salts, solvates or hydrates.

4. Compound according to claim 1 of formula:




10 in which R_1 , R_3 and R_4 are as defined for (I) in claim 1, T represents a (C_1 - C_3)alkylene and Z represents an amino group, a 2-hydroxyethylamino, a 2-(2-hydroxy)ethyloxyethylamino, a morpholinyl or a carboxylic acid, and its salts, solvates or hydrates.

5. Compound according to claim 1 of formula:



in which R₁, T and Z are as defined for (I) in claim 1 or one of its salts, solvates or hydrates.

6. Compound of formula:



in which R₁, R₂, Cy, T and X are as defined for (I)

- X is a halogen or a sulphonic acid derivative;
 - or alternatively X represents an azido group,
- or one of its salts, solvates or hydrates.

7. Compound according to claim 1, characterized in that it is one of the compounds below :

- *5-chloro-3-spiro-[4-(2-morpholinoethoxy)cyclo-hexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzene-sulphonyl]indolin-2-one;
- *5-ethoxy-3-spiro-[4-(2-aminoethoxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzene-sulphonyl]indolin-2-one;
- *5-ethoxy-3-spiro-[4-(2-(N-methyl-N-(2-hydroxy-ethyl)amino)ethyl)oxycyclohexane]-1-[4-(N-*tert*-butyl-carbamoyl)-2-methoxybenzenesulphonyl]indolin-2-one;

*5-ethoxy-3-spiro-[4-(2-morpholinoethyloxy)cyclo-hexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzyl]-indolin-2-one;

*5-ethoxy-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxy-benzenesulphonyl]-3-spiro-[4-(2-morpholinoethyloxy)-cyclohexane]indolin-2-one;

5 *5-ethoxy-3-spiro-(4-carboxymethyloxy)cyclohexane)-1-(4-N-*tert*-butylcarbamoyl)-2-methoxybenzenesulphonyl]-indolin-2-one;

*5-ethoxy-3-spiro-[4-(2-morpholinoethyloxy)cyclo-hexane]-1-[4-(N-*tert*-amylbutylcarbamoyl)-2-methoxy-benzenesulphonyl]indolin-2-one;

10 *5-ethoxy-3-spiro-[4-(2-carboxyethyloxy)cyclo-hexane]-1-[4-(N-*tert*-amylcarbamoyl)-2-methoxybenzene-sulphonyl]indolin-2-one;

*5-ethoxy-1-[4-(N',N'-diethylureido)-2-methoxy-benzenesulphonyl]-3-spiro-[4-(2-dimethylaminoethyloxy)-cyclohexane]indolin-2-one;

*5-Ethoxy-3-spiro-[4-(2-(4-ethoxypiperidino)- ethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

15 *5-Ethoxy-3-spiro-[4-(2-(glycylaminoethyloxy)- cyclohexane)-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxy-benzenesulfonyl]indolin-2-one ;

*5-Ethoxy-3-spiro-[4-(2-(N,N-dimethylglycylamino)- ethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

20 *5-Chloro-3-spiro-[4-(N-(3-dimethylaminopropyl)-carbamoylmethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

*5-Ethoxy-3-spiro-[4-(2-(4-dimethylaminobutyl- amino)ethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

25 *5-Ethoxy-3-spiro-[4-(2-(2-hydroxyethylamino)- ethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

*5-Ethoxy-3-spiro-[4-(2-(L-γ-glutamylamino)- ethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

30 *5-Ethoxy-3-spiro-[4-(2-(L-pyroglutamylamino)- ethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;

*5-Ethoxy-3-spiro-[4-(2-(2-(2-hydroxyethyloxy)- ethylamino)ethyloxy)cyclohexane]-1-[4-(N-*tert*-butylcarbamoyl)-2-methoxybenzenesulfonyl]indolin-2-one ;


or their pharmaceutically acceptable salts, solvates or hydrates.

8. Process for the preparation of a compound of formula (I) according to any one of Claims

35 1 to 5 and 7, characterized in that:

(1) either when Z = NR¹¹R¹², in which R¹¹ and R¹² are as defined for (I):


(1a) when at least one of the R_{11} and R_{12} radicals is different from hydrogen, a compound of formula:



- 5 in which R_1 , R_2 , R_3 , R_4 , W , Cy and T are as defined for (I) and in which X is a halogen or a sulphonic acid derivative, is reacted with a derivative of formula ZH in a solvent selected from dimethylformamide, tetrahydrofuran or acetonitrile, at temperatures of between 0° and 120°C ;


- 10 (1b) When R_{11} and $R_{12} = H$, the compound (IIA), in which X is an azido, is reduced to amino;

(2) or, when $Z = -\text{COOH}$, a compound of formula:




- 15 in which R_1 , R_2 , W , R_3 , R_4 and Cy are as defined for (I) and T' represents $T-\text{CH}_2-$, is oxidized in an acid solvent at a temperature of between 0°C and 100°C , alkali metal dichromates or alkali metal or alkaline-earth metal permanganates;

(3) or a compound of formula:




5 in which R_1 , R_2 , Cy, T and Z are as defined for (I), is reacted with a compound of formula:




in which W, R_3 and R_4 are as defined for (I) and Hal represents a halogen atom, in an anhydrous solvent in the presence of a metal hydride or an alkali metal alkoxide at temperatures of between -40° and 25°C ;

10 (4) or, when $Z = -\text{COOH}$, a compound of formula:




in which R_1 , R_2 and Cy are as defined above for (I) and T represents $\text{T}-\text{CH}_2$, is oxidized to (I), then the acid thus obtained of formula:

15



in which R_1 , R_2 , Cy and T are as defined above for (I), is subsequently optionally protected by a protective group for the carboxylic acid, in order to obtain the intermediate of formula:




- in which R_1 , R_2 , Cy and T are as defined for (I) and P represents a protective group chosen from an alkyl, a *tert*-butyl or a benzyl, and, finally, this compound
- 5 (II' BP) is subjected to the action of a derivative of formula (2) in order to obtain, after deprotection, a compound (I); one of its quaternary ammoniums, oxides, sulphones or salts.
9. Pharmaceutical composition containing, as active principle, a compound of formula (I) according to Claim 1 or one of its pharmaceutically acceptable salts,
- 10 hydrates or solvates.
10. Pharmaceutical composition containing, as active principle, a compound of formula (I.1) according to Claim 2 or one of its pharmaceutically acceptable salts, hydrates or solvates.
11. Pharmaceutical composition containing, as active principle, a compound of formula (I.2) according to Claim 3 or one of its pharmaceutically acceptable salts,
- 15 hydrates or solvates.
12. Pharmaceutical composition containing, as active principle, a compound of formula (I.3) according to Claim 4 or one of its pharmaceutically acceptable salts, hydrates or solvates.
- 20 13. Pharmaceutical composition containing, as active principle, a compound of formula (I.4) according to Claim 5 or one of its pharmaceutically acceptable salts, hydrates or solvates.
14. Pharmaceutical composition containing, as active principle, a compound according to Claim 7.
- 25 15. Pharmaceutical composition according to any one of Claims 9 to 14 also containing another active principle.
16. Pharmaceutical composition according to Claim 15, characterized in that the other active principle is a specific antagonist of the angiotensin II receptor.
17. Pharmaceutical composition according to Claim 16, characterized in that the
- 30 specific antagonist of the angiotensin II receptor is irbesartan.

Amended sheet

ABSTRACT

The subject of the invention is indolin-2-one derivatives of formula:

5



in which:

- W represents a -CH₂- or -SO₂- group;
- 10 - Cy forms, with the carbon to which it is bonded, a non-aromatic, saturated or unsaturated C₃-C₁₂ hydrocarbon ring which is optionally condensed or substituted by one or a number of (C₁-C₇)alkyl groups, it being possible for the said groups to substitute the same carbon atom one or
- 15 a number of times, or by a C₃-C₆ spirocycloalkyl;
- T represents a (C₁-C₄)alkylene which is optionally interrupted by a (C₃-C₆)cycloalkylene, the said alkylenes optionally being substituted one or a number of times on the same carbon atom by a (C₁-C₃)alkyl; or alternatively
- 20 T represents a direct bond;
- Z represents in particular an amino group;
- R₁ and R₂, as well as R₃ and R₄, are either hydrogen or substituents, such as, for example, a halogen, an alkyl, and the like.

25

Application: Medicines having an affinity for vasopressin and/or oxytocin receptors.

X	Original	Supplemental	Substitute
---	----------	--------------	------------

My residence, citizenship and post office address are given below under my name.

"Indolin-2-one derivatives, process for their production and the pharmaceutical compositions containing them."

is attached hereto.

Application Serial No.

X was filed on 24 October 1996 as PCT International

and was amended under PCT Article 19 on (if applicable).

I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application in accordance with Section 1.56 of Title 37 of the Code of Federal Regulations.

I hereby claim foreign priority benefit under Section 119 (a) - (d) of Title 35 of the United States Code of any foreign application(s) for patent or inventor's certificate or of any PCT application(s) designating at least one country other than the United States identified below and also identify below any foreign application(s) for patent or inventor's certificate or any PCT application(s) designating at least one country other than the United States filed by me on the same subject matter and having a filing date before that of the application(s) from which priority is claimed:

Country	Number	Filing Date	Priority Claimed	
			Yes	No
FRANCE	95 12533	24 October 1995	X	

I hereby claim benefit under Section 120 of Title 35 of the United States Code of any United States application(s) or PCT application(s) designating the United States identified below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner provided by the first paragraph of Section 112 of Title 35 of the United States Code, I acknowledge my duty to disclose material information of which I am aware as defined in Section 1.56 of Title 37 of the Code of Federal Regulations which occurred between the filing date of the prior application(s) and the national or PCT filing date of this application:

Application Serial No. Filing Date Status

I hereby appoint Mary P. Bauman, Reg. No. 31,926; Michael D. Alexander, Reg. No. 36,080; and Paul E. Dupont, Reg. No. 27,438, or any of them my attorneys or agents with full power of substitution and revocation to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO:

DIRECT TELEPHONE CALLS TO:

Patent Department
Sanofi Pharmaceuticals, Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355

MICHAEL D. ALEXANDER

Telephone No. (610) 889-8802

I hereby declare that all statements made herein and in the above-identified specification of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

100 Full name of first joint inventor

Loïc FOULON

Inventor's signature

Date 1st April 1998

Residence 14 rue de l'Ousse, 34120 PINSAGUEL, France

Citizenship French


FRX

200 Full name of second joint inventor Georges GARCIA
Inventor's signature [Signature] Date 1st April 1998
Residence 76 Chemin de la Bergerie, 34110 FRONTIGNAN, France
Citizenship French FRX

300 Full name of third joint inventor Claudine SERRADEIL-LE GAL
Inventor's signature [Signature] Date 1st April 1998
Residence 45 avenue des Troubadours, 31750 ESCALQUENS, France
Citizenship French FRX

400 Full name of fourth joint inventor Gérard VALETTE
Inventor's signature [Signature] Date 1st April 1998
Residence 8 rue de Montségur, 31120 LACROIX-FALGARDE, France
Citizenship French FRX

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
 - ☐ All sheets must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
Pages _____ do not meet these requirements.
 - ☐ Papers are not ☐ flexible, ☐ strong, ☐ smooth, ☐ non-shiny, ☐ durable, and ☐ white.
 - ☐ Papers are not ☐ typewritten or mechanically printed ☐ in permanent ink ☐ on one side.
 - ☐ Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
 - ☐ Papers contain hand lettering.
2. Drawings are not in compliance and were not scanned because:
 - ☐ The drawings or copy of drawings are not suitable for electronic reproduction.
 - ☐ All drawings sheets are not either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
 - ☐ Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").
3. Page(s) _____ are not of sufficient ☐ clarity, ☐ contrast and ☐ quality for electronic reproduction.
4. Page(s) _____ are missing.
5. OTHER: No Drawings